WO1996017947A1 - Packaging cell lines for generation of high titers of recombinant aav vectors - Google Patents
Packaging cell lines for generation of high titers of recombinant aav vectors Download PDFInfo
- Publication number
- WO1996017947A1 WO1996017947A1 PCT/US1995/015892 US9515892W WO9617947A1 WO 1996017947 A1 WO1996017947 A1 WO 1996017947A1 US 9515892 W US9515892 W US 9515892W WO 9617947 A1 WO9617947 A1 WO 9617947A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aav
- cell
- packaging
- vector
- cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4712—Cystic fibrosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Definitions
- This invention relates to gene therapy, and more specifically to materials and methods used for the generation of high titers of recombinant AAV vectors for use in gene therapy procedures.
- AAV vectors may have utility for gene therapy but heretofore a significant obstacle has been the inability to generate sufficient quantities of such recombinant vectors in amounts that would be clinically useful for human gene therapy application. This is a particular problem for in vivo applications such as direct delivery to the lung.
- Adeno-associated virus (AAV) vectors are among a small number of recombinant virus vector systems which have been shown to have utility as in vivo gene transfer agents (reviewed in Carter, 1992, Current Opinion in Biotechnology- 3:533-539; Muzcyzka, 1992, Curr. Top. Microbiol. Immunol. 158:97-129) and thus are potentially of great importance for human gene therapy.
- AAV vectors are capable of high- frequency stable DNA integration and expression in a variety of cells including cystic fibrosis (CF) bronchial and nasal epithelial cells (see, e.g., Flotte et al., 1992a, Am. J. Respir. Cell Mol. Biol.
- AAV may not require active cell division for stable expression which would be a clear advantage over retroviruses, especially in tissue such as the human airway epithelium where most cells are terminally differentiated and non-dividing.
- AAV is a defective parvovirus that grows only in cells in which certain functions are provided by a co-infecting helper virus (see Fig. 1) .
- a co-infecting helper virus see Fig. 1 .
- Examples of co-infecting viruses that provide helper functions for AAV growth and replication are adenoviruses, herpesviruses and in some cases poxviruses such as vaccinia.
- the nature of the helper function is not entirely known but appears to be some indirect effect of the helper virus which renders the cell permissive for AAV replication. This belief is supported by the observation that in certain cases AAV replication may occur at a low level of efficiency in the absence of helper virus co-infection if the cells are treated with agents that are either genotoxic or that disrupt the cell cycle.
- AAV may replicate to a limited extent in the absence of helper virus in certain unusual conditions, as noted above, the more general result is that infection of cells with AAV in the absence of helper functions results in integration of AAV into the host cell genome.
- the integrated AAV genome may be rescued and replicated to yield a burst of infectious progeny AAV particles if cells containing an integrated AAV provirus are superinfected with a helper virus such as adenovirus. Because the integration of AAV appears to be an efficient event, this suggested that AAV would be a useful vector for introducing genes into cells for stable expression for uses such as human gene therapy.
- AAV has a very broad host range with neither any obvious species nor tissue specificity and will replicate in virtually any cell line of human, simian or rodent origin provided an appropriate helper is present.
- AAV is ubiquitous and has been isolated from a wide variety of animal species including most mammalian and several avian species.
- AAV has not been associated with the cause of any disease.
- AAV is not a transforming or oncogenic virus.
- AAV integration into chromosomes of human cell lines does not cause any significant alteration in the growth properties or morphological characteristics of the cells.
- These properties of AAV also recommend it as a potentially useful human gene therapy vector because most of the other viral systems proposed for this application such as retroviruses, adenoviruses, herpesviruses, or poxviruses are disease-causing viruses.
- AAV particles are comprised of a protein capsid having three capsid proteins, VPl, VP2, and VP3, and enclosing a DNA genome.
- the AAV DNA genome is a linear single-stranded DNA molecule having a molecular weight of about 1.5 x 10 ⁇ daltons or approximately 4680 nucleotides long. Strands of either complementary sense, "plus” or “minus” strands, are packaged into individual particles but each particle has only one DNA molecule. Equal numbers of AAV particles contain either a plus or minus strand.
- Either strand is equally infectious and replication occurs by conversion of the parental infecting single strand to a duplex form and subsequent ampli ication of a large pool of duplex molecules from which progeny single strands are displaced and packaged into capsids.
- Duplex or single-strand copies of AAV genomes inserted into bacterial plasmids or phagemids are infectious when transfected into adenovirus-infected cells, and this has allowed the study of AAV genetics and the development of AAV vectors.
- the AAV2 genome has two copies of a 145-nucleotide-long
- ITR inverted terminal repeat
- the unique region contains three transcription promoters p5, pl9, and p40 (Laughlin et al., 1979, Proc. Natl. Acad. Sci. USA. 76:5567-5571) that are used to express the rep and cap genes.
- the ITR sequences are required in cis and are sufficient to provide a functional origin of replication (ori ) and also are sufficient to provide signals required for integration into the cell genome as well as for efficient excision and rescue from host cell chromosomes or from recombinant plasmids.
- the ITR can function directly as a transcription promoter in an AAV vector (Flotte et al., 1993, vide supra) .
- the rep and cap genes are required in tr ⁇ ms to provide functions for replication and encapsidation of viral genome respectively.
- the rep gene is expressed from two promoters, p5 and pl9. Transcription from p5 yields an unspliced 4.2 kb mRNA which encodes a protein, Rep78, and a spliced 3.9 kb mRNA which encodes a protein, Rep68. Transcription from pl9 yields an unspliced mRNA which encodes Rep52 and a spliced 3.3 kb mRNA which encodes Rep40.
- the four Rep proteins all comprise a common internal region sequence but differ with respect to their amino and carboxyl terminal regions.
- Rep78 and Rep68 are required for AAV duplex DNA replication, but Rep52 and Rep40 appear to be needed for progeny,- single- strand DNA accumulation. Mutations in Rep78 and Rep68 are phenotypically Rep- whereas mutations affecting only Rep52 and Rep40 are Rep+ but Ssd-. Rep68 and Rep78 bind specifically to the hairpin conformation of the AAV ITR and possess several enzyme activities required for resolving replication at the AAV termini. Rep52 and Rep40 have none of these properties.
- the Rep proteins, primarily Rep78 and Rep68 exhibit several pleiotropic regulatory activities including positive and negative regulation of AAV genes and expression from some heterologous promoters, as well as inhibitory effects on cell growth (Tratschin et al., 1986, Mol. Cell.
- Virology. 166:154-165) reported a very low level expression of some Rep proteins in certain cell lines after stable integration of AAV genomes.
- the proteins VPl, VP2, and VP3 all share a common overlapping sequence but differ in that VPl and VP2 contain additional amino terminal sequence. All three are coded from the same cap gene reading frame expressed from a spliced 2.3 kb mRNA transcribed from the p40 promoter. VP2 and VP3 are generated from the same mRNA by use of alternate initiation codons. VPl is coded from a minor mRNA using 3' donor site that is 30 nucleotides upstream from the 3' donor used for the major mRNA that encodes VP2 and VP3. VPl, VP2, and VP3 are all required for capsid production. Mutations which eliminate all three proteins (Cap-) prevent accumulation of single- strand progeny AAV DNA whereas mutations in the VPl amino- terminus (Lip-, Inf-) permit single-strand production but prevent assembly of stable infectious particles.
- AAV infectious genomes of AAV were constructed by insertion of double-strand molecules of AAV into plasmids by procedures such as GC tailing (Samulski et al. , 1982, Proc. Natl. Acad. Sci. USA. 79:2077-2081), addition of synthetic linkers containing restriction endonuclease (Laughlin et al., 1983, Gene. 23:65-73) or by direct, blunt-end ligation (Senapathy & Carter, 1984, J. Biol. Chem..
- AAV vector construction were defined as reviewed recently (Carter, 1992, Current Opinions in Biotechnology. 3:533-539; Muzyczka, 1992, Current Topics in Microbiology and Immunology. 158:97-129).
- AAV vectors are constructed in AAV recombinant plasmids by substituting portions of the AAV coding sequence with foreign DNA to generate a vector plasmid.
- the terminal (ITR) portions of the AAV sequence must be retained intact because these regions are required in cis for several functions including excision from the plasmid after transfection, replication of the vector genome and integration and rescue from a host cell genome.
- the vector can then be packaged into an AAV particle to generate an AAV transducing virus by transfection of the vector plasmid into cells that are infected by an appropriate helper virus such as adenovirus or herpesvirus.
- an appropriate helper virus such as adenovirus or herpesvirus.
- the vector plasmid In order to achieve replication and encapsidation of the vector genome into AAV particles, the vector plasmid must be complemented for any AAV functions required in trans , namely rep and cap, that were deleted in construction of the vector plasmid.
- the transducing vector must be generated at sufficiently high titers that it is practicable as a delivery system. This is especially important for gene therapy stratagems aimed at in vivo delivery of the vector.
- the required dose of transducing vector may be in excess of 10 10 .
- the vector preparations must be free of wild-type AAV virus.
- the attainment of high titers of AAV vectors has been difficult for several reasons including preferential encapsidation of wild-type AAV genomes if they are present or generated by recombination, and the inability to generate sufficient complementing functions such as rep or cap.
- Useful cell lines expressing such complementing functions have not been generated, in part, because of several inhibitory functions of the rep gene.
- the first AAV vectors that were described contained foreign reporter genes such as neo or cat or dhfr that were expressed from AAV transcription promoters or an SV40 promoter (Tratschin et al., 1984b, Mol. Cell. Biol. 4:2072-2081; Hermonat & Muzyczka, 1984, Proc. Natl. Acad. Sci. USA. 81:6466-6470; Tratschin et al., 1985, Mol. Cell. Biol. 5:3251- 3260; McLaughlin et al., 1988, J. Virol.. 62:1963-1973; Lebkowski et al., 1988 Mol. Cell. Biol.. 7:349-356).
- foreign reporter genes such as neo or cat or dhfr that were expressed from AAV transcription promoters or an SV40 promoter
- AAV rep or cap gene still met with generation of wild-type AAV and still produced very low transduction frequencies on human cell lines.
- McLaughlin et al., 1988 reported that AAV rep- cap- vectors containing the neo gene packaged with the same packaging plasmid used earlier by Hermonat & Muzyczka
- Lebkowski et al., 1988 packaged AAV vectors which did not contain either a rep or cap gene and used an ori- packaging plasmid pBalA identical to that used earlier by Tratschin et al., (1984b, 1985) and reported transduction frequencies that were similarly low, in that for several human cell lines not more than 1% of the cells could be transduced to geneticin resistance even with their most concentrated vector stocks.
- Lebkowski et al. , (1988) did not report the actual vector titers in a meaningful way but the biological assays showing not more than 1% transduction frequency when 5 x 10 6 cells were exposed to three ml of vector preparation indicates that the titer was less than 2 x 10 4 .
- the pBal packaging plasmid contains overlapping ho ology with the ITR sequence in the vector and leads to generation by recombination of wild-type AAV.
- Laface et al., (1988) used the same vector as that used by Hermonat & Muzyczka (1984) prepared in the same way and obtained a transduction frequency of 1.5% in murine bone marrow cultures again showing very low titer.
- Sa ulski et al. (1987, J. Virol.. 61:3096-3101) constructed a plasmid called pSub201 which was an intact AAV genome in a bacterial plasmid but which had a deletion of 13 nucleotides at the extremity of each ITR and thus was rescued and replicated less efficiently than other AAV plasmids that contained the entire AAV genome.
- Samulski et al. (1989, J ⁇ _ Virol.. 63:3822-3828) constructed AAV vectors based on pSub20l but deleted for rep and cap and containing either a hyg or neo gene expressed from an SV40 early gene promoter.
- pAAV/Ad packaged these vectors by co-transfection with a packaging plasmid called pAAV/Ad which consisted of the entire AAV nucleotide sequence from nucleotide 190 to 4490 enclosed at either end with one copy of the adenovirus ITR.
- pAAV/Ad a packaging plasmid which consisted of the entire AAV nucleotide sequence from nucleotide 190 to 4490 enclosed at either end with one copy of the adenovirus ITR.
- the AAV rep and cap genes were expressed from the natural AAV promoters p5, pl9 and p40.
- the function of the adenovirus ITR in pAAV/Ad was thought to be to enhance the expression level of AAV capsid proteins.
- rep is expressed from its homologous promoter and is negatively regulated and thus its expression is limited.
- Chatterjee et al., and Wong et al. used a packaging system known to give only low titer and which can lead to generation of wild-type AAV genomes because of the overlapping homology in the vector and packaging sequences.
- Other reports have described the use of AAV vectors to express genes in human lymphocytes (Muro-Cacho et al., 1992, J. Immunotherapy. 11:231-237) or a human erythroid leukemia cell line (Walsh et al., 1992, Proc. Natl. Acad. Sci. USA. 89:7257-7261) with vectors based on the pSub201 vector plasmid and pAAV/Ad packaging plasmid. Again, titers of vector stocks were not reported and were apparently low because a selective marker gene was used to identify those cells that had been successfully transduced with the vector.
- AAV vectors may have potential utility as vectors for treatment of human disease by gene therapy.
- the ability to generate sufficient amounts of AAV vectors has been a severe limitation on the development of human gene therapy using AAV vectors.
- One aspect of this limitation is that there have been very few studies using AAV vectors in in vivo animal models (see, e.g., Flotte et al., 1993b; and Kaplitt et al., 1994, Nature Genetics 8:148-154). This is generally a reflection of the difficulty associated with generating sufficient amounts of AAV vector stocks having a high enough titer to be useful in analyzing in vivo delivery and gene expression.
- AAV gene therapy has been the relative inefficiency of the vector packaging systems that have been used. Because of the lack of cell lines expressing the AAV trans complementing functions, such as rep and cap, packaging of AAV vectors has been achieved in adenovirus-infected cells by co-transfection of a packaging plasmid and a vector plasmid. The efficiency of this process may be limited by the efficiency of transfection of each of the plasmid constructs, and by the level of expression of Rep proteins from the packaging plasmids described to date. Each of these problems appears to relate to the biological activities of the AAV Rep proteins. In addition, as noted above, all of the packaging systems described above have the ability to generate wild-type AAV by recombination.
- Lebkowski et al. introduce rep and cap genes into the cell genome but the method again requires the use of episomal AAV transducing vectors comprising an Epstein-Barr virus nuclear antigen (EBNA) gene and an Epstein-Barr virus latent origin of replication; and, again, the only information relative to titer showed a fairly low titer.
- EBNA Epstein-Barr virus nuclear antigen
- AAV vectors can achieve in vivo gene transfer in the respiratory tract, for example, but high titers are critical so as to allow for the delivery of sufficiently high multiplicity of vector in as small a volume as possible.
- Stable, helper-free AAV packaging cell lines have been elusive, mainly due to the activities of Rep protein, which down-regulates its own expression and can negatively affect the host cell.
- Rep protein which down-regulates its own expression and can negatively affect the host cell.
- the approaches described in this invention effectively circumvent these problems and have allowed for substantial improvements in packaging efficiency.
- a method of producing a mammalian cell capable of high efficiency packaging of a recombinant AAV (rAAV) vector comprising the steps of: (a) providing a mammalian cell which comprises a stably integrated AAV cap gene operably linked to a promoter, and a stably integrated AAV rep gene operably linked to a heterologous promoter; (b) replicating the cell of step (a) to produce a population of cells; (c) introducing a helper virus to the population of cells of step (b) ; and (d) selecting a cell exhibiting helper-virus-inducible rep protein activity.
- rAAV recombinant AAV
- step (a) comprises the combined rep and cap genes of AAV in which the p5 promoter has been replaced by a heterologous promoter.
- heterologous promoter is a mouse metallothionein I (mMT-I) promoter.
- mMT-I mouse metallothionein I
- a mammalian cell capable of high efficiency packaging of a recombinant AAV (rAAV) vector, said cell comprising a stably integrated cap gene operably linked to a promoter, and a stably integrated rep gene operably linked to a heterologous promoter; wherein said cell exhibits helper- virus-inducible rep protein activity.
- rAAV recombinant AAV
- said heterologous promoter is a mouse metallothionein I (mMT-I) promoter.
- ITR inverted terminal repeat
- a method of packaging a recombinant AAV vector comprising the steps of: (a) providing an AAV packaging cell of embodiment 10; (b) introducing a recombinant AAV vector, said vector comprising a polynucleotide sequence of interest located between two AAV inverted terminal repeat (ITR) regions; (c) introducing a helper virus; and (d) incubating the cell under conditions suitable for replication and packaging of AAV.
- ITR inverted terminal repeat
- a method of packaging a recombinant AAV vector comprising the steps of: (a) providing an AAV packaging cell of embodiment 15 which comprises a stably integrated rAAV vector; (b) introducing a helper virus; and (c) incubating the cell under conditions suitable for replication and packaging of AAV.
- CFTR cystic fibrosis transmembrane conductance regulator
- Figure 1 is a diagram of plasmid pMt-rep/cap//pKO-neo, as described in Example 1.
- Figure 2 is a reproduction of Southern blots demonstrating that packaging cells produced according to the present invention have sufficient rep activity to replicate an incoming rAAV vector, as described in Example 4.
- Figure 3 is a reproduction of Southern blots demonstrating that packaging cells produced according to the present invention are capable of replicating an AAV genome in the presence of adenovirus, and that this activity can be used to quantify the number of infectious viral particles present in a given sample, as described in Example 5.
- Figure 4 is a reproduction of Southern blots demonstrating that packaging cells produced according to the present invention express rep protein and are able to replicate recombinant AAV plasmid DNA genomes introduced by transfection, as described in Example 6.
- Figure 5 is a reproduction of Southern blots demonstrating that the infectious rAAV titering assay described in Example 5 had proceeded for a sufficient amount of time to reach a maximum, as described in Example ' 7.
- Figures 6 and 7 are reproductions of Southern blots demonstrating that packaging cells produced according to the present invention can replicate and package rAAV vector genomes into infectious virions by either transfection or infection, as described in Examples 9 and 10.
- Figure 8 is a reproduction of a Southern blot demonstrating that packaging cells produced according to the present invention possess sufficient rep activity to recognize, excise and amplify an integrated rAAV vector, as described in Example 11. DETAILED DESCRIPTION OF THE INVENTION
- AAV vectors are recombinant constructs of the AAV virus comprising AAV components necessary for replication and encapsidation, along with a heterologous polynucleotide encoding a protein of interest. These recombinant AAV vectors are potentially powerful tools for human gene therapy, particularly for diseases such as cystic fibrosis and sickle cell anemia.
- a major advantage of AAV vectors over other approaches to gene therapy is that they do not require ongoing replication of the target cell in order to integrate permanently into the cell's genome.
- the invention described herein provides methods and materials for use in the production of high titers of recombinant AAV vectors for use in gene therapy. It also provides methods and materials for determining the relative infectious titer of rAAV preparations.
- polypeptide polypeptide
- peptide protein
- proteins that are post- translationally modified through reactions that include glycosylation, acetylation and phosphorylation.
- Polynucleotide refers to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides, or analogs thereof. This term refers only to the primary structure of the molecule. Thus, double- and single-stranded DNA, as well as double- and single- stranded RNA are included. It also includes modified polynucleotides such as methylated or capped polynucleotides.
- Recombinant as applied to a polynucleotide, means that the polynucleotide is the product of various combinations of cloning, restriction and/or ligation steps, and other procedures that result in a construct that is distinct from a polynucleotide found in nature.
- Sequence overlap occurs when the nucleotides share a homologous sequence of sufficient length and identity that recombination is facilitated.
- the level of homology and corresponding frequency of recombination increase with increasing length of the homologous sequences and with their level of shared identity.
- the level of homology that will pose a concern in a given system can be determined theoretically and confirmed experimentally, as is known in the art.
- recombination can be substantially reduced or eliminated if the overlapping sequence is less than about a 25 nucleotide sequence if it is at least 80% identical over its entire length, or less than about a 50 nucleotide sequence if it is at least 70% identical over its entire length.
- a "vector” refers to a recombinant plasmid or virus that comprises a polynucleotide to be delivered into a host cell, either in vitro or in vivo.
- the polynucleotide to be delivered sometimes referred to as a "target polynucleotide” may comprise a coding sequence of interest in gene therapy.
- a “recombinant AAV vector” refers to vector comprising one or more polynucleotides of interest tha are flanked by AAV inverted terminal repeat sequences (ITRs) .
- ITRs AAV inverted terminal repeat sequences
- Such rAAV vectors can be replicated and packaged into infectious viral particles when present in a host cell that has been infected with a suitable helper virus and is expressing the AAV rep and cap genes.
- AAV "rep” and “cap” genes (encoding replication and encapsidation proteins, respectively) have been found in all AAV serotypes examined, and are described above and in the references cited therein. Typically, the rep and cap genes are found adjacent to each other in the AAV genome, and they are generally conserved among AAV serotypes.
- helper virus for AAV refers to a second virus that allows wild-type AAV (which is a "defective" parvovirus) to b replicated and packaged by a host cell.
- helper viruses include adenoviruses, herpesviruses and poxviruses such as vaccinia.
- Packaging refers to a series of subcellular events that results in the assembly and ' encapsidation of an rAAV vector. Thus, when a suitable vector plasmid is introduced into a packaging cell line under appropriate conditions, it will be assembled into a vector viral particle.
- Heterologous means derived from a genotypically distinct entity from that of the rest of the entity to which it is compared.
- a polynucleotide introduced by genetic engineering techniques into a different cell type is a heterologous polynucleotide (and, when expressed, can encode a heterologous polypeptide) .
- a promoter that is removed from its native coding sequence and operably linked to a different coding sequence is a heterologous promoter.
- Promoter refers to a geno ic region that enhances the transcription of a gene or coding sequence to which it is operably linked.
- operably linked refers to a juxtaposition, wherein the components so described are in a relationship permitting them to function in their intended manner.
- a promoter is operably linked to a coding sequence if the promoter promotes transcription of the coding sequence.
- An operably linked promoter is usually in cis configuration with the coding sequence, but is not necessarily contiguous with it.
- “Host cells”, “cell lines”, “cell cultures”, and other such terms denote higher eukaryotic cells, most preferably mammalian cells, which can be used as recipients for recombinant vectors or other transfer polynucleotides, and include the progeny of the original cell that was transduced. It is understood that the progeny of a single cell may not necessarily be completely identical (in morphology or in genomic complement) to the original parent cell.
- “Stable integration" of a polynucleotide into a cell means that the polynucleotide has been introduced into a chromosome or mini-chromosome of the cell and, therefore, becomes a relatively permanent part of the cellular genome.
- “episomes” such as plasmids can sometimes be maintained for many generations (particularly if kept under selective pressure)
- genetic material carried episomally is generally more susceptible to loss than chromosomally- integrated material.
- chromatin structure of eukaryotic chromosomes can influence the level of expression of an integrated polynucleotide; and we believe that such effects can sometimes prove beneficial in situations such as those described herein (in which the level of expression of the AAV rep gene can have negative effects upon cellular metabolism) .
- the selection of stable cell lines having properties that are particularly desirable in the context of the present invention, are described in the Detailed Description and Examples below. 6/17947 PC17US95/15892
- Efficiency when used in describing a cell line refers to the useful properties of the line; in particular, the growth rate, and (for packaging cell lines) the number of virus particles produced per cell. "High efficiency packaging” indicates production of at least 100 viral particles per cell.
- the method for producing high titers of recombinant•AAV vectors comprises several steps.
- the general strategy involves preparation of mammalian packaging cell lines that comprise a stably integrated AAV cap gene operably linked to a promoter, and a stably integrated AAV rep gene operably linked to a heterologous promoter.
- Packaging cells are then infected or transfected with a plasmid comprising the AAV ITR regions and the target polynucleotide.
- suitable conditions including suitable growth conditions and infection with a competent helper virus
- expression of the rep and cap genes of the packaging cell results in the synthesis of rep and cap proteins which mediate replication and encapsidation of the
- AAV vector Providing a polynucleotide of interest (also referred to as a "target polynucleotide”) in- between the AAV ITR sequences of the rAAV vector, thus results in packaging of the target polynucleotide into an infectious rAAV particle which can be used to deliver the polynucleotide to a desired host cell.
- a polynucleotide of interest also referred to as a "target polynucleotide”
- the proportion of wild-type AAV i.e., particles not containing the target polynucleotide
- the presence of contaminating wild-type AAV limits the therapeutic potential of rAAV vector preparations.
- the p5 promoter region is replaced with a different promoter.
- the packaging cell lines of the present invention enable the efficient production of rAAV preparations that are of high titer and are substantially free of any contaminating wild- type AAV; attributes that are especially useful in the context of AAV-mediated gene therapy.
- the degree of relatedness is further suggested by heteroduplex analysis which reveals extensive cross-hybridization between serotypes along the length of the genome; and the presence of analogous self-annealing segments at the termini that correspond to ITRs.
- the similar infectivity patterns also suggest that the replication functions in each serotype are under similar regulatory control.
- the parental lines from which packaging cells are generated may be obtained from any cell line that is susceptible to AAV infection, and amenable to culture in vitro.
- AAV has a very broad host range and has been isolated from a variety of mammalian cell types, including simian, human and rodent cells.
- human cell lines in which appropriate helper functions can be expressed are typically preferred.
- Such human cell lines from which the packaging cell lines may be derived include, for example, Hela, A549, 293, KB, Detroit, and WI38 cells. We initially selected both Hela cells and A549 cells for demonstrations of the present invention. As described in the Examples below, we were readily able to generate packaging cells from both parental lines tested.
- the rep gene is under regulation of the p5 promoter, which is itself strongly down-regulated by rep expression.
- the cells are provided with a stably integrated AAV cap gene operably linked to a promoter, and a stably integrated AAV rep gene operably linked to a heterologous promoter; as described and illustrated herein. Any heterologous promoter that is not strongly down-regulated by rep gene expression is suitable; but inducible promoters are preferred because constitutive expression of the rep gene can have a negative impact on the host cell.
- inducible promoters are known in the art; including, by way of illustration, heavy metal ion inducible promoters (such as metallothionein promoters) ; steroid hormone inducible promoters (such as the MMTV promoter or growth hormone promoters) ; and promoters such as those from T7 phage which are active in the presence of T7 RNA polymerase.
- inducible promoters are those that are induced by the helper virus that is used to complement the replication and packaging of the rAAV vector.
- helper-virus-inducible promoters include for example, the adenovirus early gene promoter which is inducible by adenovirus E1A protein; the adenovirus major late promoter; the herpesvirus promoter which is inducible by herpesvirus proteins such as VP16 or 1CP ; as well as vaccinia or poxvirus inducible promoters.
- the Examples below illustrate a generally applicable method that can be used to test putative promoters to readily determine whether or not they are helper-virus-inducible and whether or not they will be useful in the generation of high efficiency packaging cells.
- the method involves replacing the p5 promoter of the AAV rep gene with the putative helper-virus-inducible promoter (either known in the art or identified using well-known techniques such as linkage to promoter-less "reporter" genes) .
- the AAV rep-cap genes (with p5 replaced) , preferably linked to a positive selectable marker such as an antibiotic resistance gene, are then stably integrated into a suitable host cell (such as the Hela or A549 cells exemplified below) .
- Cells that are able to grow relatively well under selection conditions are then tested for their ability to express the rep and cap genes upon addition of a helper virus.
- As an initial test for rep and/or cap expression cells can be readily screened using immunofluorescence to detect rep and/or cap proteins (as illustrated in the Examples below) . Confirmation of packaging capabilities and efficiencies can then be determined by functional tests for replication and packaging of incoming rAAV vectors (also illustrated below) .
- the p5 promoter with a helper-virus-inducible promoter derived from the mouse etallothionein gene, and used the resulting constructs to generate packaging cell lines capable of producing high titers of rAAV particles.
- the AAV cap gene is also stably integrated into the packaging cell line.
- the rep and cap genes are introduced into the parental line together, by using a plasmid that contains them both (essentially as they are arranged in the AAV genome, except for replacement of the sequences upstream of rep, i.e. the p5 promoter region) .
- plasmid designated pMt-rep/cap//pKO-neo shown in Figure 1 .
- the plasmid contains a heterologous promoter linked to a region containing the rep-cap genes. The rest of the rep-cap region, including the pl9 promoter and the p40 promoter are retained.
- the plasmid also contains an AAV polyadenylation signal.
- the components of native AAV that are not present in the plasmid include the p5 promoter region (which has been substituted by the heterologous promoter) and the ITRs (which are present in the vector plasmid to be introduced separately) .
- Cells transfected with rep and cap genes as described above are then selected from untransfected cells according to methods that are routine in the art. Most conveniently, selection is accomplished by linking the rep and cap genes to one or more selectable markers (such as antibiotic resistance genes) .
- selectable markers such as antibiotic resistance genes
- the neo-resistance gene was included next to the rep-cap sequences.
- selectable markers are driven by constitutive promoters; and preferably, such markers are introduced in an opposite orientation relative to the AAV rep-cap genes since that tends to reduce the potential for the promoter driving the selectable marker to effect expression of the rep gene (which can be detrimental to the host cell) .
- the cell lines are exposed to the antibiotic for which resistance has been provided (geneticin was used in the case of the constructs referred to above) .
- the selectable marker is included on the same plasmid as the rep-cap sequences; and both are stably integrated into the host genome.
- the plasmid Mt-rep/cap//pKOneo for example, geneticin- resistant cells would be expected to possess an integrated copy of the neo gene as well as pMt-rep/cap. Since the rep sequences cannot readily be lost in our system, the prior art would predict that the recipient cells would exhibit reduced growth rates.
- our constructs were introduced into exemplary mammalian host cells (Hela and A549) , the rate of proliferation of the geneticin-resistant clones was not significantly affected in either of the cell lines.
- packaging cells that are capable of replicating at least one half as rapidly as the parental cells, and capable of producing more than 100 rAAV particles/cell.
- the cells grow at least two-thirds as rapidly as the parental line, and produce more than 250 rAAV particles/cell.
- packaging cells that replicate substantially as rapidly as the parent cells (at least about 80% of the rate), and that produce more ' than about 500 rAAV particles per cell.
- the packaging cell line is supplied with a recombinant AAV vector comprising AAV inverted terminal repeat (ITR) regions surrounding one or more polynucleotides of interest (or "target" polynucleotides) .
- ITR inverted terminal repeat
- the target polynucleotide is operably linked to a promoter, either its own or a heterologous promoter.
- a promoter either its own or a heterologous promoter.
- suitable promoters are known in the art, the choice of which depends on the desired level of expression of the target polynucleotide; whether one wants constitutive expression, inducible expression, cell-specific or tissue-specific expression, etc.
- the rAAV vector will also contain a positive selectable marker in order to allow for selection of cells that have been infected by the rAAV vector.
- Negative selectable markers can also be included; as a means of selecting against those same cells should that become necessary or desirable.
- those constructs involve direct translational fusions between a dominant positive selectable marker a negative selectable marker.
- Preferred positive selectable markers are derived from genes selected from the group consisting of hph, neo, and gpt
- preferred negative selectable markers are derived from genes selected from the group consisting of cytosine dea inase, HSV-I TK, VZV TK, HPRT, APRT and gpt
- Especially preferred markers are bifunctional selectable fusion genes wherein the positive selectable marker is derived from hph or neo, and the negative selectable marker is derived from cytosine deaminase or a TK gene.
- CFTR operably linked to a promoter.
- CFTR polypeptides that are capable of reconstructing CFTR functional deficiencies in cells derived from cystic fibrosis patients.
- Rich et al. (1991, Science, 253: 205-207) described a CFTR derivative missing amino acid residues 708-835, that was capable of transporting chloride and capable of correcting a naturally occurring CFTR defect.
- Egan et al. (1993) described another CFTR derivative (comprising about 25 amino acids from an unrelated protein followed by the sequence of native CFTR beginning at residue 119) that was also capable of restoring electrophysiological characteristics of normal CFTR.
- polynucleotides include, but are not limited to: (i) polynucleotides encoding proteins useful in other forms of gene therapy to relieve deficiencies caused by missing, defective or sub-optimal levels of a structural protein or enzyme; (ii) polynucleotides that are transcribed into anti-sense molecules; (iii) polynucleotides that are transcribed into decoys that bind transcription or translation factors; (iv) polynucleotides that encode cellular modulators such as cytokines; (v) polynucleotides that can make recipient cells susceptible to specific drugs, such as the herpes virus thymidine kinase gene; and (vi) polynucleotides for cancer therapy, such as the wild-type p53 tumor suppressor cDNA for replacement of the missing or damaged p53 gene associated with some lung and breast cancer
- the same packaging cell line can be used for any of these applications.
- the plasmid comprising the specific target polynucleotide is introduced into the packaging cell for production of the AAV vector by one of several possible methods; including, for example, electroporation.
- Helper virus can be introduced before, during or after introduction of the rAAV vector. As illustrated in Example 10, the plasmid can be co-infected into the culture along with the helper virus.
- the cells are then cultured for a suitable period, typically 2-5 days, in conditions suitable for replication and packaging as known in the art (see references above and examples below) . Lysates are prepared, and the recombinant AAV vector particles are purified by techniques known in the art.
- the recombinant AAV vector is itself stably integrated into a clone of the packaging cell line.
- a stable, vector-containing packaging line can be grown and stored until ready for use.
- the user simply infects the cells with helper virus and cultures the cells under conditions suitable for replication and packaging of AAV (as described below) .
- the amount of helper virus and the incubation time influence the amount of rep activity, they can be readily optimized and kept constant, as illustrated below.
- To conduct the assay aliquots of the packaging cell line are introduced with a standard amount of helper virus and serial dilutions of the rAAV preparation to be tested.
- the relative infectious titer of the AAV is indicated by the amount of replicated AAV present in each aliquot after suitable incubation; and can be compared to a preparation of known titer.
- the examples presented below are provided as a further guide to the practitioner of ordinary skill in the art, and are not to be construed as limiting the invention in any way.
- Example l Construction of a plasmid encoding the rep-cap sequences operably linked to a heterologous promoter
- a plasmid containing the wild type rep and cap genes from deoxyribonucleotide 311 to 4493 of the AAV genome
- mMt-I mouse metallothionein I
- This construction effectively removes both ITR's and substitutes the mMt-I promoter for the p5 promoter while maintaining all of the AAV reading frames, the pl9 and p40 promoters and the polyadenylation signal.
- pKOneo contains the neo gene ⁇ providing resistance to neomycin and gentamicin) under control of the SV40 early promoter; as well as SV40 small t intron and SV40 polyadenylation signal oriented in the opposite transcriptional direction relative to pMt-rep/cap (Ito et al. 1994 Cancer Lett. 76:33-39).
- pMt-rep/cap//pKO-neo The resulting plasmid, designated pMt-rep/cap//pKO-neo, is shown in Figure 1.
- Example 2 Integration of the rep-cap genes into mammalian cell lines
- DMEM Dulbecco's modified Eagle's medium
- the cells were plated at low density in the presence of l mg/ml active component geneticin (Gibco-BRL) . Individual colonies were ring cloned, expanded and maintained in l mg/ml geneticin.
- Gabco-BRL active component geneticin
- the selectable marker is included on the same plasmid as the rep-cap sequences; and both are stably integrated into the host genome.
- the plasmid Mt-rep/cap//pKOneo for example, geneticin- resistant cells would be expected to possess an integrated copy of the neo gene as well as pMt-rep/cap. Since the rep sequences cannot readily be lost in our system, the prior art would predict that the recipient cells would exhibit reduced growth rates.
- PBS phosphate buffered saline
- the cells were then washed three additional times with PBS and incubated overnight with "WT" medium (1% nonfat dry milk, 0.5 mg/ml bovine serum albumin, 150 mM NaCl, 50 mM HEPES (pH 7.5), 0.1% Tween 20 and 1 mM NaN 3 ) .
- WT "WT” medium
- Anti-rep antibody (rabbit anti-Rep78.93; Trempe et al. 1987 Virology 161:18-28) was diluted 1:250 in WT and 100 ⁇ l added to each well for 1 hour at room temperature (RT) .
- the cells were washed five times with WT and then incubated with 100 ⁇ l of a 1:100 dilution of anti-rabbit IgG FITC conjugate secondary antibody (Sigma Chemical Corp.) in the dark for 1 hour at RT.
- the cells were then washed three times with WT and two times with PBS in the dark and examined with an Axioskop H fluorescence microscope (Zeiss, Germany) .
- rep protein was detectable in a number of the cells examined (8 out of 23 A549 clones and 3 out of 28 Hela clones) .
- the addition of heavy metals did not significantly affect the observed rep expression under any conditions.
- helper-virus-inducible promoter is a general one that can be readily applied to any promoter of potential interest by simply swapping it into rep constructs and screening for colonies as we describe herein.
- exemplary clones (of Hela and A549 origin) were tested for their ability to replicate recombinant AAV genomes after infection, as described below.
- Replication activity of IF+ cells We examined whether the pMt-rep/cap//pKO-neo transfected cell lines exhibited functional replication activity.
- MOI 25 pfu/cell
- the culture medium from each well was removed to a labeled tube and any cells still attached to the culture dish were trypsinized and pooled with cells present in the media.
- the cell suspension was centrifuged at 3000 rpm for 5 min. , after which the supernatant was removed and total nucleic acid was prepared from the cell pellet (according to Ausubel et al. (ed.) 1987 Current Protocols in Molecular Biology Greene Publishing Associates, Brooklyn, N.Y.) .
- Negative controls for the experiment included the incubation of 1.2 x 10 8 AAVCFTR particles on either cell line without adenovirus. Fifteen micrograms of nucleic acid for each sample, as well as untreated Hela clone 37 DNA +/- 20 pg of AAVCFTR plasmid (positive control for Southern) , was digested with EcoRI, subjected to gel electrophoresis, transferred to nitrocellulose and probed with a 1.488 kb EcoRI fragment from within the CFTR cDNA. Lanes 15-18 (Fig.
- a hybridization signal migrating at 1.488 kb is present in DNA isolated from both the Hela clone 37 and A549 clone 20 cell lines after infection by AAVCFTR virus and adenovirus (Fig. 2, lanes 1, 2 and 8).
- Example 5 rAAV infectious titer assays Additional rep activity assays were performed in order to determine whether there was a linear relationship between incoming AAVCFTR virus and replicated AAVCFTR sequences (which could be exploited as the basis of an rAAV infectious titer assay) .
- Three log dilutions from 1.2 x 10 9 to 1.2 x 10 7 AAVCFTR particles, as determined by slot blot hybridization, were cultured in 2.5 ml media on 2.5 x 10 5 Hela clone 37 cells plus adenovirus (MOI 25 pfu/cell) for 48 hours in a 6 well culture dish.
- MOI 25 pfu/cell
- packaging cells produced according to the present invention are capable of replicating an AAV genome in the presence of adenovirus, and that this activity can be used to quantify the number of infectious viral particles present in a given sample.
- the particle number was determined by slot blot hybridization of the AAVCFTR virus preparation and may reflect the contribution of infectious and defective AAVCFTR particles; whereas the infectious assay described above should only detect infectious particles.
- AAV recombinant AAV
- Current methods for the production of recombinant AAV (rAAV) virus include the transient transfection of plasmid vectors containing the rAAV sequences. One or more steps are undertaken to remove the plasmid DNA from a rAAV preparation.
- AAVCFTR plasmid DNA was incubated directly onto packaging cells (Hela clone 37) +/- adenovirus to determine whether the above-described infection assay would detect non-viral DNA.
- AAVCFTR plasmid (10 ⁇ g) was electroporated as previously described into 4 x 10 6 Hela clone 37 cells and then transferred to a 100 mm culture dish.
- FIG. 4 shows the hybridization pattern of the endogenous CFTR gene and the migration of CFTR cDNA (20 pg) spiked into human genomic DNA when digested with EcoRI and probed with the 1.488 kb CFTR cDNA fragment. Electroporation of the AAVCFTR plasmid into Hela clone 37 cells resulted in a signal migrating at 1.488 k (Fig.4, lane 1) and represents the amount of AAVCFTR plasmid present in these cells 24 hours after transfection.
- Lanes 5-8 show the results of incubating 1 ⁇ g, 100 ng, 10 ng and 1 ng AAVCFTR plasmid, respectively, on Hela clone 37 cell in the presence of adenovirus.
- Example 8 Adenovirus titration of rAAV infectious titer assay
- MOI 2.5 ml culture media +/- adenovirus
- a slight signal migrating at 1.488 kb can be detected in DNA isolated from Hela clone 37 cells incubated with supernatant derived from the minus adenovirus control and reflects a small amount of contaminating input AAVCFTR plasmid from the electroporation (Fig. 7, lane 1).
- Supernatant derived from a duplicate well cultured with adenovirus and titered on Hela clone 37 cells revealed significantly more hybridization migrating at 1.488 kb relative to control conditions (Fig. 7, compare lanes 3 and 1) .
- Example 11 Rescue and amplification of an integrated rAAV 'vector from packaging cells
- Packaging cells derived from Hela clone 37
- a recombinant AAV vector designated rAAV-CMV-Hygro
- hygromycin resistance gene operably linked to the CMV enhancer/promoter
- a stable, polyclonal line was derived by selection in 300 ⁇ g/ml hygromycin.
- the polyclonal, hygro-resistant Hela clone 37 line (2.5 x 10 5 cells/well) was seeded onto a 6 well dish for infection with adenovirus
- Lane 1 represents DNA isolated from the parental Hela clone 37 cell line, and hence does not contain the hygro-resistance gene.
- Lane 2 contains DNA from the polyclonal, hygro-resistant Hela clone 37 line which at this exposure time does not show the presence of the resistance gene which is present at an average of about 1 copy/well (data not shown) .
- DNA isolated from a duplicate well containing the hygro-resistant Hela clone 37 cells treated with adenovirus was run in lane 3.
- the hybridization present at 1048 bp represents material derived from the excision and amplification of the integrated AAVCMVHygro vector integrated in the Hela clone cells.
- the addition of wild-type AAV to the adenovirus infection gave similar results (lane 4) .
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Data Exchanges In Wide-Area Networks (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8517764A JPH10511264A (en) | 1994-12-06 | 1995-12-06 | Packaging cell lines for the production of high titer recombinant AAV vectors |
AU45963/96A AU707866B2 (en) | 1994-12-06 | 1995-12-06 | Packaging cell lines for generation of high titers of recombinant AAV vectors |
EP95944069A EP0796339A1 (en) | 1994-12-06 | 1995-12-06 | Packaging cell lines for generation of high titers of recombinant aav vectors |
US09/731,941 US6924128B2 (en) | 1994-12-06 | 2000-12-06 | Packaging cell lines for generation of high titers of recombinant AAV vectors |
US11/071,401 US20050148076A1 (en) | 1994-12-06 | 2005-03-02 | Packaging cell lines for generation of high titers of recombinant AAV vectors |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35021994A | 1994-12-06 | 1994-12-06 | |
US08/350,219 | 1994-12-06 | ||
US48057595A | 1995-06-07 | 1995-06-07 | |
US08/480,575 | 1995-06-07 |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US48057595A Continuation | 1994-12-06 | 1995-06-07 | |
US48057595A Continuation-In-Part | 1994-12-06 | 1995-06-07 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US56416795A A-371-Of-International | 1994-12-06 | 1995-12-06 | |
US09/731,941 Continuation US6924128B2 (en) | 1994-12-06 | 2000-12-06 | Packaging cell lines for generation of high titers of recombinant AAV vectors |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1996017947A1 true WO1996017947A1 (en) | 1996-06-13 |
WO1996017947A9 WO1996017947A9 (en) | 1996-10-03 |
Family
ID=26996529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/015892 WO1996017947A1 (en) | 1994-12-06 | 1995-12-06 | Packaging cell lines for generation of high titers of recombinant aav vectors |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0796339A1 (en) |
JP (1) | JPH10511264A (en) |
AU (1) | AU707866B2 (en) |
CA (1) | CA2207927A1 (en) |
WO (1) | WO1996017947A1 (en) |
Cited By (274)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997049824A1 (en) * | 1996-06-24 | 1997-12-31 | Medigene Ag | System for the production of aav vectors |
WO1998010088A1 (en) * | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
WO1998010086A1 (en) * | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Methods using cre-lox for production of recombinant adeno-associated viruses |
WO1998027207A1 (en) * | 1996-12-18 | 1998-06-25 | Targeted Genetics Corporation | Recombinase-activatable aav packaging cassettes for use in the production of aav vectors |
US5866552A (en) * | 1996-09-06 | 1999-02-02 | The Trustees Of The University Of Pennsylvania | Method for expressing a gene in the absence of an immune response |
WO1999014354A1 (en) * | 1997-09-19 | 1999-03-25 | The Trustees Of The University Of The Pennsylvania | Methods and vector constructs useful for production of recombinant aav |
WO1999015685A1 (en) * | 1997-09-19 | 1999-04-01 | The Trustees Of The University Of Pennsylvania | Methods and cell line useful for production of recombinant adeno-associated viruses |
WO1999027110A1 (en) * | 1997-11-21 | 1999-06-03 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Hormone-dependent forms of the adeno-associated virus, rep proteins, dna sequences coding for them, vectors containing them, and regulatory methods of their intracellular activity |
WO1999061641A1 (en) * | 1998-05-22 | 1999-12-02 | University College London | Aav-vector production |
US6174871B1 (en) | 1995-02-28 | 2001-01-16 | The Regents Of The University Of California | Gene therapies for enhancing cardiac function |
US6197754B1 (en) | 1996-10-18 | 2001-03-06 | Board Of Regents, The University Of Texas System | Suppression of tumor growth by a mini-E1A gene |
US6294370B1 (en) | 1997-06-24 | 2001-09-25 | Medigene Ag | System for the production of AAV vectors |
US6306830B1 (en) | 1996-09-05 | 2001-10-23 | The Regents Of The University Of California | Gene therapy for congestive heart failure |
US6346415B1 (en) | 1997-10-21 | 2002-02-12 | Targeted Genetics Corporation | Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors |
US6537540B1 (en) | 1999-05-28 | 2003-03-25 | Targeted Genetics Corporation | Methods and composition for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders |
US6541258B2 (en) | 1996-12-18 | 2003-04-01 | Targeted Genetics Corporation | AAV split-packaging genes and cell lines comprising such genes for use in the production of recombinant AAV vectors |
US6541012B2 (en) | 1996-06-24 | 2003-04-01 | Christoph Bogedain | System for the production of AAV vectors |
US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US6596535B1 (en) | 1999-08-09 | 2003-07-22 | Targeted Genetics Corporation | Metabolically activated recombinant viral vectors and methods for the preparation and use |
US6642051B1 (en) | 1997-10-21 | 2003-11-04 | Targeted Genetics Corporation | Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors |
US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
US6752987B1 (en) | 1995-02-28 | 2004-06-22 | The Regents Of The University Of California | Adenovirus encoding human adenylylcyclase (AC) VI |
US6793926B1 (en) | 1999-05-27 | 2004-09-21 | Genovo, Inc. | Methods for production of a recombinant adeno-associated virus |
US6846665B1 (en) | 1999-02-10 | 2005-01-25 | Medigene Aktiengesellschaft | Method of producing a recombinant adeno-associated virus, suitable means for producing the same and use thereof for producing a medicament |
US6893865B1 (en) | 1999-04-28 | 2005-05-17 | Targeted Genetics Corporation | Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles |
US6924128B2 (en) | 1994-12-06 | 2005-08-02 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant AAV vectors |
WO2005077091A2 (en) | 2004-02-10 | 2005-08-25 | Trustees Of Dartmouth College | Nicotinamide riboside kinase compositions and methods for using the same |
US6989264B2 (en) | 1997-09-05 | 2006-01-24 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US7115391B1 (en) | 1999-10-01 | 2006-10-03 | Genovo, Inc. | Production of recombinant AAV using adenovirus comprising AAV rep/cap genes |
US7235236B2 (en) | 1995-02-28 | 2007-06-26 | The Regents Of The University Of California | Polynucleotide encoding human adenylylcyclase VI and uses thereof for enhancing cardiac function |
US7271002B2 (en) | 2001-11-09 | 2007-09-18 | United States Of America, Represented By The Secretary, Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
WO2007148971A2 (en) | 2006-06-21 | 2007-12-27 | Amsterdam Molecular Therapeutics B.V. | Vectors with modified initiation codon for the translation of aav-rep78 useful for production of aav in insect cells |
EP1916258A2 (en) | 1999-08-09 | 2008-04-30 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs |
WO2008067480A2 (en) | 2006-11-29 | 2008-06-05 | Nationwide Children's Hospital | Myostatin inhibition for enhancing muscle and/or improving muscle function |
EP1930418A1 (en) | 1998-09-04 | 2008-06-11 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
EP1939300A1 (en) | 1999-05-28 | 2008-07-02 | Targeted Genetics Corporation | Methods and compositions for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders |
EP1944362A2 (en) | 1997-09-05 | 2008-07-16 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of recombinant AAV vectors |
WO2010109053A1 (en) | 2009-03-27 | 2010-09-30 | Proyeto De Biomedicina Cima, S.L. | Methods and compositions for the treatment of cirrhosis and liver fibrosis |
EP2311967A2 (en) | 2005-10-20 | 2011-04-20 | Amsterdam Molecular Therapeutics B.V. | Improved AAV vectors produced in insect cells |
WO2011054994A1 (en) | 2009-11-05 | 2011-05-12 | Proyecto De Biomedicina Cima, S.L. | Regulated expression systems |
WO2013164793A2 (en) | 2012-05-04 | 2013-11-07 | Novartis Ag | Viral vectors for the treatment of retinal dystrophy |
EP2767298A2 (en) | 2010-11-23 | 2014-08-20 | Presage Biosciences, Inc. | Therapeutic methods and compositions for solid delivery |
WO2014165349A1 (en) | 2013-04-04 | 2014-10-09 | Trustees Of Dartmouth College | Compositions and methods for in vivo excision of hiv-1 proviral dna |
WO2014168953A1 (en) | 2013-04-08 | 2014-10-16 | University Of Iowa Research Foundation | Chimeric adeno-associated virus/ bocavirus parvovirus vector |
WO2014172669A1 (en) | 2013-04-20 | 2014-10-23 | Research Institute At Nationwide Children's Hospital | Recombinant adeno-associated virus delivery of exon 2-targeted u7snrna polynucleotide constructs |
US8945918B2 (en) | 2006-08-24 | 2015-02-03 | Virovek, Inc. | Expression in insect cells of genes with overlapping open reading frames, methods and compositions therefor |
US9133482B2 (en) | 2011-04-21 | 2015-09-15 | Nationwide Children's Hospital, Inc. | Recombinant virus products and methods for inhibition of expression of myotilin |
WO2016057975A2 (en) | 2014-10-10 | 2016-04-14 | Research Institute At Nationwide Children's Hospital | Guided injections for aav gene transfer to muscle |
WO2016122791A1 (en) | 2015-01-30 | 2016-08-04 | The Regents Of The University Of California | Spinal subpial gene delivery system |
WO2016126993A1 (en) | 2015-02-04 | 2016-08-11 | Washington University | Anti-tau constructs |
US9415121B2 (en) | 2008-12-19 | 2016-08-16 | Nationwide Children's Hospital | Delivery of MECP2 polynucleotide using recombinant AAV9 |
US9415119B2 (en) | 2009-05-02 | 2016-08-16 | Genzyme Corporation | Gene therapy for neurodegenerative disorders |
WO2016135558A2 (en) | 2015-02-23 | 2016-09-01 | Crispr Therapeutics Ag | Materials and methods for treatment of hemoglobinopathies |
US9434928B2 (en) | 2011-11-23 | 2016-09-06 | Nationwide Children's Hospital, Inc. | Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides |
US9469851B2 (en) | 2011-07-25 | 2016-10-18 | Nationwide Children's Hospital, Inc. | Recombinant virus products and methods for inhibition of expression of DUX4 |
WO2016187017A1 (en) | 2015-05-15 | 2016-11-24 | Mcivor R Scott | Adeno-associated for therapeutic delivery to central nervous system |
US9539307B2 (en) | 2012-09-17 | 2017-01-10 | The Research Institute At Nationwide Children's Hospital | Compositions and methods for treating amyotrophic lateral sclerosis |
WO2017064546A1 (en) | 2015-09-24 | 2017-04-20 | Crispr Therapeutics Ag | Novel family of rna-programmable endonucleases and their uses in genome editing and other applications |
WO2017075335A1 (en) | 2015-10-28 | 2017-05-04 | Voyager Therapeutics, Inc. | Regulatable expression using adeno-associated virus (aav) |
WO2017072590A1 (en) | 2015-10-28 | 2017-05-04 | Crispr Therapeutics Ag | Materials and methods for treatment of duchenne muscular dystrophy |
WO2017077386A1 (en) | 2015-11-06 | 2017-05-11 | Crispr Therapeutics Ag | Materials and methods for treatment of glycogen storage disease type 1a |
WO2017093804A2 (en) | 2015-12-01 | 2017-06-08 | Crispr Therapeutics Ag | Materials and methods for treatment of alpha-1 antitrypsin deficiency |
WO2017109757A1 (en) | 2015-12-23 | 2017-06-29 | Crispr Therapeutics Ag | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration |
US9725719B2 (en) | 2013-11-05 | 2017-08-08 | The Research Institute At Nationwide Children's Hospital | Compositions and methods for inhibiting NF-κB and SOD-1 to treat amyotrophic lateral sclerosis |
WO2017134529A1 (en) | 2016-02-02 | 2017-08-10 | Crispr Therapeutics Ag | Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome |
WO2017139381A1 (en) | 2016-02-08 | 2017-08-17 | University Of Iowa Research Foundation | Methods to produce chimeric adeno-associated virus/bocavirus parvovirus |
WO2017141109A1 (en) | 2016-02-18 | 2017-08-24 | Crispr Therapeutics Ag | Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome |
WO2017147467A1 (en) | 2016-02-26 | 2017-08-31 | Research Institute At Nationwide Children's Hospital | Recombinant virus products and methods for inducing dux4 exon skipping |
WO2017158422A1 (en) | 2016-03-16 | 2017-09-21 | Crispr Therapeutics Ag | Materials and methods for treatment of hereditary haemochromatosis |
WO2017173411A1 (en) | 2016-04-02 | 2017-10-05 | Research Institute At Nation Wide Children's Hospital | Modified u6 promoter system for tissue specific expression |
WO2017172606A1 (en) | 2016-03-28 | 2017-10-05 | The Regents Of The University Of California | Method and composition for treating neuronal hyper-excitability |
WO2017172772A1 (en) | 2016-03-28 | 2017-10-05 | Dimension Therapeutics | Methods of heat inactivation of adenovirus |
WO2017181015A1 (en) | 2016-04-15 | 2017-10-19 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery of micro-dystrophin to treat muscular dystrophy |
WO2017180976A1 (en) | 2016-04-15 | 2017-10-19 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery of b-sarcoglycan and microrna-29 and the treatment of muscular dystrophy |
WO2017182881A2 (en) | 2016-04-18 | 2017-10-26 | Crispr Therapeutics Ag | Materials and methods for treatment of hemoglobinopathies |
WO2017191503A1 (en) | 2016-05-05 | 2017-11-09 | Crispr Therapeutics Ag | Materials and methods for treatment of hemoglobinopathies |
WO2018002783A1 (en) | 2016-06-29 | 2018-01-04 | Crispr Therapeutics Ag | Materials and methods for treatment of friedreich ataxia and other related disorders |
WO2018002812A1 (en) | 2016-06-29 | 2018-01-04 | Crispr Therapeutics Ag | Materials and methods for treatment of myotonic dystrophy type 1 (dm1) and other related disorders |
WO2018002762A1 (en) | 2016-06-29 | 2018-01-04 | Crispr Therapeutics Ag | Materials and methods for treatment of amyotrophic lateral sclerosis (als) and other related disorders |
WO2018007980A1 (en) | 2016-07-06 | 2018-01-11 | Crispr Therapeutics Ag | Materials and methods for treatment of pain related disorders |
WO2018007871A1 (en) | 2016-07-08 | 2018-01-11 | Crispr Therapeutics Ag | Materials and methods for treatment of transthyretin amyloidosis |
WO2018007976A1 (en) | 2016-07-06 | 2018-01-11 | Crispr Therapeutics Ag | Materials and methods for treatment of pain related disorders |
US9873868B2 (en) | 2003-01-22 | 2018-01-23 | Duke University | Constructs for expressing lysosomal polypeptides |
WO2018020323A2 (en) | 2016-07-25 | 2018-02-01 | Crispr Therapeutics Ag | Materials and methods for treatment of fatty acid disorders |
WO2018071817A1 (en) | 2016-10-14 | 2018-04-19 | Dimension Therapeutics | Use of tonicifying agents to enhance recombinant adeno-associated virus yield |
WO2018093925A1 (en) | 2016-11-15 | 2018-05-24 | Laoharawee Kanut | Method for improving neurological function in mpsi and mpsii and other neurological disorders |
WO2018094251A1 (en) | 2016-11-17 | 2018-05-24 | Kaspar Brian K | Intrathecal delivery of recombinant adeno-associated virus encoding methyl-cpg binding protein 2 |
US10017832B2 (en) | 2015-08-25 | 2018-07-10 | Washington University | Compositions and methods for site specific recombination at asymmetric sites |
WO2018132747A1 (en) | 2017-01-13 | 2018-07-19 | University Of Iowa Research Foundation | Bocaparvovirus small noncoding rna and uses thereof |
US10047130B2 (en) | 2014-03-18 | 2018-08-14 | Washington University | Methods and compositions for red-shifted chromophore substitution for optogenetic applications |
WO2018154387A1 (en) | 2017-02-22 | 2018-08-30 | Crispr Therapeutics Ag | Compositions and methods for gene editing |
WO2018154418A1 (en) | 2017-02-22 | 2018-08-30 | Crispr Therapeutics Ag | Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders |
WO2018154462A2 (en) | 2017-02-22 | 2018-08-30 | Crispr Therapeutics Ag | Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders |
WO2018170408A1 (en) | 2017-03-17 | 2018-09-20 | Research Institute At Nationwide Children's Hospital, Inc. | Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy |
EP3415167A1 (en) | 2012-08-01 | 2018-12-19 | Nationwide Children's Hospital | Intrathecal delivery of recombinant adeno-associated virus 9 |
WO2019011817A1 (en) | 2017-07-08 | 2019-01-17 | Genethon | Treatment of spinal muscular atrophy |
WO2019012336A2 (en) | 2017-03-17 | 2019-01-17 | Newcastle University | Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy |
US10196636B2 (en) | 2011-04-21 | 2019-02-05 | Nationwide Children's Hospital, Inc. | Recombinant virus products and methods for inhibition of expression of myotilin |
WO2019028306A2 (en) | 2017-08-03 | 2019-02-07 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
US10214730B2 (en) | 2011-04-19 | 2019-02-26 | The Research Foundation For The State University Of New York | Adeno-associated-virus Rep sequences, vectors and viruses |
WO2019067982A2 (en) | 2017-09-29 | 2019-04-04 | Massachusetts Eye And Ear Infirmary | Production of adeno-associated viruses in insect cells |
WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
WO2019079240A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
WO2019079527A1 (en) | 2017-10-17 | 2019-04-25 | Casebia Therapeutics Limited Liability Partnership | Compositions and methods for gene editing for hemophilia a |
WO2019081982A1 (en) | 2017-10-26 | 2019-05-02 | Crispr Therapeutics Ag | Materials and methods for treatment of hemoglobinopathies |
WO2019094253A1 (en) | 2017-11-08 | 2019-05-16 | Avexis Inc. | Means and method for preparing viral vectors and uses of same |
WO2019092505A1 (en) | 2017-11-09 | 2019-05-16 | Casebia Therapeutics Llp | Self-inactivating (sin) crispr/cas or crispr/cpf1 systems and uses thereof |
WO2019097305A2 (en) | 2017-05-12 | 2019-05-23 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
WO2019102381A1 (en) | 2017-11-21 | 2019-05-31 | Casebia Therapeutics Llp | Materials and methods for treatment of autosomal dominant retinitis pigmentosa |
WO2019118935A1 (en) | 2017-12-14 | 2019-06-20 | Casebia Therapeutics Limited Liability Partnership | Novel rna-programmable endonuclease systems and their use in genome editing and other applications |
WO2019123430A1 (en) | 2017-12-21 | 2019-06-27 | Casebia Therapeutics Llp | Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp) |
WO2019123429A1 (en) | 2017-12-21 | 2019-06-27 | Casebia Therapeutics Llp | Materials and methods for treatment of usher syndrome type 2a |
WO2019140330A1 (en) | 2018-01-12 | 2019-07-18 | Casebia Therapeutics Limited Liability Partnership | Compositions and methods for gene editing by targeting transferrin |
WO2019150196A1 (en) | 2018-02-05 | 2019-08-08 | Crispr Therapeutics Ag | Materials and methods for treatment of hemoglobinopathies |
WO2019150203A1 (en) | 2018-02-05 | 2019-08-08 | Crispr Therapeutics Ag | Materials and methods for treatment of hemoglobinopathies |
WO2019161310A1 (en) | 2018-02-16 | 2019-08-22 | Casebia Therapeutics Limited Liability Partnership | Compositions and methods for gene editing by targeting fibrinogen-alpha |
WO2019183150A1 (en) | 2018-03-19 | 2019-09-26 | Casebia Therapeutics Limited Liability Partnership | Novel rna-programmable endonuclease systems and uses thereof |
WO2019204668A1 (en) | 2018-04-18 | 2019-10-24 | Casebia Therapeutics Limited Liability Partnership | Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease |
WO2019210137A1 (en) | 2018-04-27 | 2019-10-31 | Voyager Therapeutics, Inc. | Methods for measuring the potency of aadc viral vectors |
WO2019222444A2 (en) | 2018-05-16 | 2019-11-21 | Voyager Therapeutics, Inc. | Directed evolution |
WO2019222328A1 (en) | 2018-05-15 | 2019-11-21 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of parkinson's disease |
WO2019222441A1 (en) | 2018-05-16 | 2019-11-21 | Voyager Therapeutics, Inc. | Aav serotypes for brain specific payload delivery |
WO2019222329A1 (en) | 2018-05-15 | 2019-11-21 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
EP3572516A1 (en) | 2014-08-09 | 2019-11-27 | The Research Institute at Nationwide Children's Hospital | Methods and materials for activating an internal ribosome entry site in exon 5 of the dmd gene |
WO2019236949A1 (en) | 2018-06-08 | 2019-12-12 | Avexis Inc. | Cell-based assay for measuring drug product potency |
WO2019238692A1 (en) | 2018-06-12 | 2019-12-19 | The University Of Bristol | Materials and methods for modulating intraocular and intracranial pressure |
WO2019241486A1 (en) | 2018-06-13 | 2019-12-19 | Voyager Therapeutics, Inc. | Engineered 5' untranslated regions (5' utr) for aav production |
WO2019245973A1 (en) | 2018-06-18 | 2019-12-26 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy |
WO2019246125A1 (en) | 2018-06-18 | 2019-12-26 | Research Institute At Nationwide Children's Hospital | Recombinant adeno-associated virus products and methods for treating dystroglycanopathies and laminin-deficient muscular dystrophies |
WO2020006458A1 (en) | 2018-06-29 | 2020-01-02 | Research Institute At Nationwide Children's Hospital | Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a |
WO2020010042A1 (en) | 2018-07-02 | 2020-01-09 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord |
WO2020023612A1 (en) | 2018-07-24 | 2020-01-30 | Voyager Therapeutics, Inc. | Systems and methods for producing gene therapy formulations |
US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
WO2020047268A1 (en) | 2018-08-29 | 2020-03-05 | Research Institute At Nationwide Children's Hospital | Products and methods for inhibition of expression of mutant gars protein |
US10584337B2 (en) | 2016-05-18 | 2020-03-10 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
EP3622821A1 (en) | 2013-05-15 | 2020-03-18 | Regents of the University of Minnesota | Adeno-associated virus mediated gene transfer to the central nervous system |
WO2020069461A1 (en) | 2018-09-28 | 2020-04-02 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
WO2020072844A1 (en) | 2018-10-05 | 2020-04-09 | Voyager Therapeutics, Inc. | Engineered nucleic acid constructs encoding aav production proteins |
WO2020072849A1 (en) | 2018-10-04 | 2020-04-09 | Voyager Therapeutics, Inc. | Methods for measuring the titer and potency of viral vector particles |
WO2020077165A1 (en) | 2018-10-12 | 2020-04-16 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
WO2020081490A1 (en) | 2018-10-15 | 2020-04-23 | Voyager Therapeutics, Inc. | EXPRESSION VECTORS FOR LARGE-SCALE PRODUCTION OF rAAV IN THE BACULOVIRUS/Sf9 SYSTEM |
WO2020081843A1 (en) | 2018-10-17 | 2020-04-23 | Casebia Therapeutics Limited Liability Partnership | Compositions and methods for delivering transgenes |
WO2020113034A1 (en) | 2018-11-30 | 2020-06-04 | Avexis, Inc. | Aav viral vectors and uses thereof |
WO2020127813A1 (en) | 2018-12-21 | 2020-06-25 | Genethon | Expression cassettes for gene therapy vectors |
WO2020142479A1 (en) | 2018-12-31 | 2020-07-09 | Research Institute At Nationwide Children's Hospital | Dux4 rna silencing using rna targeting crispr-cas13b |
WO2020150556A1 (en) | 2019-01-18 | 2020-07-23 | Voyager Therapeutics, Inc. | Methods and systems for producing aav particles |
EP3690024A1 (en) | 2014-11-05 | 2020-08-05 | The Research Institute at Nationwide Children's Hospital | Methods and materials for producing recombinant viruses in eukaryotic microalgae |
WO2020163300A1 (en) | 2019-02-04 | 2020-08-13 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus delivery of cln3 polynucleotide |
WO2020163299A1 (en) | 2019-02-04 | 2020-08-13 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus delivery of cln6 polynucleotide |
WO2020168362A1 (en) | 2019-02-15 | 2020-08-20 | Crispr Therapeutics Ag | Gene editing for hemophilia a with improved factor viii expression |
EP3702466A1 (en) | 2013-08-27 | 2020-09-02 | Research Institute at Nationwide Children's Hospital | Products and methods for treatment of amyotrophic lateral sclerosis |
WO2020174369A2 (en) | 2019-02-25 | 2020-09-03 | Novartis Ag | Compositions and methods to treat bietti crystalline dystrophy |
WO2020174368A1 (en) | 2019-02-25 | 2020-09-03 | Novartis Ag | Compositions and methods to treat bietti crystalline dystrophy |
WO2020176614A1 (en) | 2019-02-26 | 2020-09-03 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery of b-sarcoglycan and the treatment of muscular dystrophy |
WO2020186059A2 (en) | 2019-03-12 | 2020-09-17 | Crispr Therapeutics Ag | Novel high fidelity rna-programmable endonuclease systems and uses thereof |
WO2020210507A1 (en) | 2019-04-12 | 2020-10-15 | Ultragenyx Pharmaceutical Inc. | Engineered producer cell lines and methods of making and using the same |
WO2020214737A1 (en) | 2019-04-15 | 2020-10-22 | Sanford Research | Gene therapy for treating or preventing visual effects in batten disease |
WO2020214672A1 (en) | 2019-04-15 | 2020-10-22 | University Of Iowa Research Foundation | Methods and compositions for transgene expression |
WO2020223274A1 (en) | 2019-04-29 | 2020-11-05 | Voyager Therapeutics, Inc. | SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS |
WO2020225606A1 (en) | 2019-05-08 | 2020-11-12 | Crispr Therapeutics Ag | Crispr/cas all-in-two vector systems for treatment of dmd |
WO2020227515A1 (en) | 2019-05-07 | 2020-11-12 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
WO2020236352A1 (en) | 2019-05-17 | 2020-11-26 | Research Institute At Nationwide Children's Hospital | Optimized gene therapy targeting retinal cells |
WO2020264254A1 (en) | 2019-06-28 | 2020-12-30 | Crispr Therapeutics Ag | Materials and methods for controlling gene editing |
WO2021014428A1 (en) | 2019-07-25 | 2021-01-28 | Novartis Ag | Regulatable expression systems |
WO2021030125A1 (en) | 2019-08-09 | 2021-02-18 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
WO2021035120A1 (en) | 2019-08-21 | 2021-02-25 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery of alpha-sarcoglycan and the treatment of muscular dystrophy |
WO2021041485A1 (en) | 2019-08-26 | 2021-03-04 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
WO2021046155A1 (en) | 2019-09-03 | 2021-03-11 | Voyager Therapeutics, Inc. | Vectorized editing of nucleic acids to correct overt mutations |
WO2021072115A1 (en) | 2019-10-08 | 2021-04-15 | Regents Of The University Of Minnesota | Crispr-mediated human genome editing with vectors |
WO2021072129A2 (en) | 2019-10-08 | 2021-04-15 | Trustees Of Boston College | Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins |
US10980897B2 (en) | 2015-09-17 | 2021-04-20 | Research Institute At Nationwide Children's Hospital | Methods and materials for GALGT2 gene therapy |
WO2021077115A1 (en) | 2019-10-18 | 2021-04-22 | Research Institute At Nationwide Children's Hospital | Gene therapy targeting cochlear cells |
WO2021077101A1 (en) | 2019-10-18 | 2021-04-22 | Research Institute At Nationwide Children's Hospital | Materials and methods for the treatment of disorders associated mutations in the irf2bpl gene |
WO2021102435A1 (en) | 2019-11-22 | 2021-05-27 | Research Institute At Nationwide Children's Hospital | Materials and methods for treatment of disorders associated with the ighmbp2 gene |
WO2021127655A1 (en) | 2019-12-20 | 2021-06-24 | Research Institute At Nationwide Children's Hospital | Optimized gene therapy for targeting muscle in muscle diseases |
US11066456B2 (en) | 2016-02-25 | 2021-07-20 | Washington University | Compositions comprising TREM2 and methods of use thereof |
WO2021168124A1 (en) | 2020-02-18 | 2021-08-26 | Research Institute At Nationwide Children's Hospital | Aav-mediated targeting of mirna in the treatment of x-linked disorders |
WO2021188449A1 (en) | 2020-03-16 | 2021-09-23 | Ultragenyx Pharmaceutical Inc. | Methods for enhancing recombinant adeno-associated virus yield |
WO2021209521A1 (en) | 2020-04-14 | 2021-10-21 | Genethon | Vectors for the treatment of acid ceramidase deficiency |
WO2021211753A1 (en) | 2020-04-15 | 2021-10-21 | Voyager Therapeutics, Inc. | Tau binding compounds |
WO2021247995A2 (en) | 2020-06-04 | 2021-12-09 | Voyager Therapeutics, Inc. | Compositions and methods of treating neuropathic pain |
WO2021257595A1 (en) | 2020-06-15 | 2021-12-23 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery for muscular dystrophies |
US11219696B2 (en) | 2008-12-19 | 2022-01-11 | Nationwide Children's Hospital | Delivery of polynucleotides using recombinant AAV9 |
WO2022011099A1 (en) | 2020-07-08 | 2022-01-13 | Regents Of The University Of Minnesota | Modified hexosaminidase and uses thereof |
WO2022018638A1 (en) | 2020-07-21 | 2022-01-27 | Crispr Therapeutics Ag | Genome-editing compositions and methods to modulate faah for treatment of neurological disorders |
WO2022026410A2 (en) | 2020-07-27 | 2022-02-03 | Voyager Therapeutics, Inc | Compositions and methods for the treatment of niemann-pick type c1 disease |
WO2022026409A1 (en) | 2020-07-27 | 2022-02-03 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
WO2022032153A1 (en) | 2020-08-06 | 2022-02-10 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
WO2022047201A1 (en) | 2020-08-27 | 2022-03-03 | University Of Iowa Research Foundation | Gene knock-out for treatment of glaucoma |
WO2022055791A1 (en) | 2020-09-08 | 2022-03-17 | Sarepta Therapeutics, Inc. | Systemic delivery of adeno-associated virus vector expressing g-sarcoglycan and the treatment of muscular dystrophy |
WO2022060841A2 (en) | 2020-09-15 | 2022-03-24 | Research Institute At Nationwide Children's Hospital | Aav-mediated homology-independent targeted integration gene editing for correction of diverse dmd mutations in patients with muscular dystrophy |
WO2022067257A1 (en) | 2020-09-28 | 2022-03-31 | Research Institute At Nationwide Children's Hospital | Products and methods for treating muscular dystrophy |
WO2022070107A1 (en) | 2020-09-30 | 2022-04-07 | Crispr Therapeutics Ag | Materials and methods for treatment of amyotrophic lateral sclerosis |
US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
WO2022074464A2 (en) | 2020-03-05 | 2022-04-14 | Neotx Therapeutics Ltd. | Methods and compositions for treating cancer with immune cells |
WO2022094461A1 (en) | 2020-11-02 | 2022-05-05 | Biomarin Pharmaceutical Inc. | Process for enriching adeno-associated virus |
US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
WO2022115745A1 (en) | 2020-11-30 | 2022-06-02 | Research Institute At Nationwide Children's Hospital | Compositions and methods for treating facioscapulohumeral muscular dystrophy (fshd) |
WO2022133246A1 (en) | 2020-12-17 | 2022-06-23 | Vertex Pharmaceuticals Incorporated | Compositions and methods for editing beta-globin for treatment of hemaglobinopathies |
WO2022164860A1 (en) | 2021-01-27 | 2022-08-04 | Research Institute At Nationwide Children's Hospital | Materials and methods for the treatment of lysosomal acid lipase deficiency (lal-d) |
US11407997B2 (en) | 2017-02-22 | 2022-08-09 | Crispr Therapeutics Ag | Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders |
WO2022169922A1 (en) | 2021-02-03 | 2022-08-11 | Research Institute At Nationwide Children's Hospital | Compositions and methods for treating disease associated with dux4 overexpression |
WO2022170082A1 (en) | 2021-02-05 | 2022-08-11 | Regents Of The University Of Minnesota | Methods for preventing cardiac or skeletal defects in diseases including mucopolysaccharidoses |
WO2022170038A1 (en) | 2021-02-05 | 2022-08-11 | Amicus Therapeutics, Inc. | Adeno-associated virus delivery of cln3 polynucleotide |
WO2022187571A1 (en) | 2021-03-04 | 2022-09-09 | Research Institute At Nationwide Children's Hospital | Products and methods for treatment of dystrophin-based myopathies using crispr-cas9 to correct dmd exon duplications |
WO2022188797A1 (en) | 2021-03-09 | 2022-09-15 | Huigene Therapeutics Co., Ltd. | Engineered crispr/cas13 system and uses thereof |
WO2022221424A1 (en) | 2021-04-13 | 2022-10-20 | Research Institute At Nationwide Children's Hospital | Recombinant adeno-associated virus encoding methyl-cpg binding protein 2 for treating pitt hopkins syndrome via intrathecal delivery |
WO2022221529A1 (en) | 2021-04-16 | 2022-10-20 | Asklepios Biopharmaceutical, Inc. | Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response |
WO2022226334A1 (en) | 2021-04-23 | 2022-10-27 | Research Institute At Nationwide Children's Hospital | Products and methods for treating muscular dystrophy |
WO2022234295A1 (en) | 2021-05-07 | 2022-11-10 | Ucl Business Ltd | Abca4 genome editing |
US11497576B2 (en) | 2017-07-17 | 2022-11-15 | Voyager Therapeutics, Inc. | Trajectory array guide system |
WO2022245675A1 (en) | 2021-05-17 | 2022-11-24 | Sarepta Therapeutics, Inc. | Production of recombinant aav vectors for treating muscular dystrophy |
EP4101928A1 (en) | 2021-06-11 | 2022-12-14 | Bayer AG | Type v rna programmable endonuclease systems |
WO2022258753A1 (en) | 2021-06-11 | 2022-12-15 | Bayer Aktiengesellschaft | Type v rna programmable endonuclease systems |
US11534501B2 (en) | 2017-10-18 | 2022-12-27 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy |
EP4108263A2 (en) | 2021-06-02 | 2022-12-28 | Research Institute at Nationwide Children's Hospital | Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a |
WO2023283962A1 (en) | 2021-07-16 | 2023-01-19 | Huigene Therapeutics Co., Ltd. | Modified aav capsid for gene therapy and methods thereof |
US11559588B2 (en) | 2017-02-22 | 2023-01-24 | Crispr Therapeutics Ag | Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disorders |
WO2023018854A2 (en) | 2021-08-11 | 2023-02-16 | Solid Biosciences Inc. | Treatment of muscular dystrophy |
US11590210B2 (en) | 2011-06-08 | 2023-02-28 | Nationwide Children's Hospital, Inc. | Methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders |
EP4144841A1 (en) | 2021-09-07 | 2023-03-08 | Bayer AG | Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof |
WO2023034980A1 (en) | 2021-09-03 | 2023-03-09 | Bomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
WO2023034994A1 (en) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
WO2023034997A1 (en) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
WO2023034996A1 (en) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
WO2023034990A1 (en) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
WO2023034989A1 (en) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
US11603542B2 (en) | 2017-05-05 | 2023-03-14 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
WO2023042104A1 (en) | 2021-09-16 | 2023-03-23 | Novartis Ag | Novel transcription factors |
WO2023044483A2 (en) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
US11617783B2 (en) | 2015-11-16 | 2023-04-04 | Research Institute At Nationwide Children's Hospital | Repairing a mutant human titin gene using CRISPR technology |
WO2023060215A1 (en) | 2021-10-07 | 2023-04-13 | Research Institute At Nationwide Children's Hospital | Products and methods for myelin protein zero silencing and treating cmt1b disease |
WO2023060233A1 (en) | 2021-10-08 | 2023-04-13 | Amicus Therapeutics, Inc. | Biomarkers for lysosomal storage diseases |
WO2023077078A1 (en) | 2021-10-29 | 2023-05-04 | Ultragenyx Pharmaceutical Inc. | Engineered cell lines for increased production of recombinant adeno-associated virus (raav) |
WO2023091949A2 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
EP4186919A1 (en) | 2021-11-30 | 2023-05-31 | Research Institute at Nationwide Children's Hospital | Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy |
EP4198047A1 (en) | 2021-12-16 | 2023-06-21 | Genethon | Fukutin related protein gene transfer increase using modified itr sequences |
EP4198048A1 (en) | 2021-12-16 | 2023-06-21 | Genethon | Calpain-3 gene transfer increase using modified itr sequences |
EP4198046A1 (en) | 2021-12-16 | 2023-06-21 | Genethon | Alpha-sarcoglycan gene transfer increase using modified itr sequences |
EP4198134A1 (en) | 2021-12-16 | 2023-06-21 | Genethon | Gamma-sarcoglycan gene transfer increase using modified itr sequences |
WO2023122669A1 (en) | 2021-12-21 | 2023-06-29 | Research Institute At Nationwide Children's Hospital | Materials and methods for the treatment of limb girdle muscular dystrophy |
WO2023118068A1 (en) | 2021-12-23 | 2023-06-29 | Bayer Aktiengesellschaft | Novel small type v rna programmable endonuclease systems |
US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
EP4219726A1 (en) | 2021-10-15 | 2023-08-02 | Research Institute at Nationwide Children's Hospital | Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy |
WO2023168400A2 (en) | 2022-03-03 | 2023-09-07 | Research Institute At Nationwide Children's Hospital | Materials and methods for the treatment of eif2b5 mutations and diseases resulting therefrom |
US11753460B2 (en) | 2016-12-13 | 2023-09-12 | Seattle Children's Hospital | Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo |
US11752181B2 (en) | 2017-05-05 | 2023-09-12 | Voyager Therapeutics, Inc. | Compositions and methods of treating Huntington's disease |
WO2023178067A1 (en) * | 2022-03-16 | 2023-09-21 | Rutgers, The State University Of New Jersey | Controlled muscle‐specific gene delivery |
WO2023196818A1 (en) | 2022-04-04 | 2023-10-12 | The Regents Of The University Of California | Genetic complementation compositions and methods |
WO2023214346A1 (en) | 2022-05-06 | 2023-11-09 | Novartis Ag | Novel recombinant aav vp2 fusion polypeptides |
WO2023240236A1 (en) | 2022-06-10 | 2023-12-14 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of spinal muscular atrophy related disorders |
WO2023240177A1 (en) | 2022-06-08 | 2023-12-14 | Research Instiitute At Nationwide Children's Hospital | Products and methods for treating diseases or conditions associated with mutant or pathogenic kcnq3 expression |
WO2023237587A1 (en) | 2022-06-10 | 2023-12-14 | Bayer Aktiengesellschaft | Novel small type v rna programmable endonuclease systems |
WO2024011115A1 (en) | 2022-07-06 | 2024-01-11 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus delivery of cln1 polynucleotide |
US11898170B2 (en) | 2017-03-22 | 2024-02-13 | Ultragenyx Pharmaceutical Inc. | Cell culture methods involving HDAC inhibitors or rep proteins |
WO2024035782A1 (en) | 2022-08-10 | 2024-02-15 | Aav Gene Therapeutics, Inc. | Aav-mediated intramuscular delivery of insulin |
US11926653B2 (en) | 2017-10-20 | 2024-03-12 | Research Institute At Nationwide Children's Hospital | Methods and materials for NT-3 gene therapy |
WO2024059739A1 (en) | 2022-09-15 | 2024-03-21 | Voyager Therapeutics, Inc. | Tau binding compounds |
US11938193B2 (en) | 2016-01-08 | 2024-03-26 | Washington University | Compositions comprising chemerin and methods of use thereof |
WO2024064913A1 (en) | 2022-09-23 | 2024-03-28 | Sarepta Therapeutics, Inc. | Recombinant aav vectors for treating muscular dystrophy |
US11951121B2 (en) | 2016-05-18 | 2024-04-09 | Voyager Therapeutics, Inc. | Compositions and methods for treating Huntington's disease |
WO2024081706A1 (en) | 2022-10-11 | 2024-04-18 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus delivery to treat spinal muscular atrophy with respiratory distress type 1 (smard1) and charcot-marie-tooth type 2s (cmt2s) |
WO2024092171A1 (en) | 2022-10-26 | 2024-05-02 | University Of Iowa Research Foundation | Method to deliver large genes using virus and a dna recombination system |
WO2024092126A1 (en) | 2022-10-27 | 2024-05-02 | Cargo Therapeutics, Inc. | Compositions and methods for improved immunotherapies |
US11987804B2 (en) | 2018-04-27 | 2024-05-21 | Seattle Children's Hospital | Rapamycin resistant cells |
WO2024129743A2 (en) | 2022-12-13 | 2024-06-20 | Bluerock Therapeutics Lp | Engineered type v rna programmable endonucleases and their uses |
WO2024145474A2 (en) | 2022-12-29 | 2024-07-04 | Voyager Therapeutics, Inc. | Compositions and methods for regulating mapt |
US12037616B2 (en) | 2022-03-01 | 2024-07-16 | Crispr Therapeutics Ag | Methods and compositions for treating angiopoietin-like 3 (ANGPTL3) related conditions |
US12037707B2 (en) | 2018-04-05 | 2024-07-16 | Massachusetts Eye And Ear Infirmary | Methods of making and using combinatorial barcoded nucleic acid libraries having defined variation |
WO2024151982A1 (en) | 2023-01-13 | 2024-07-18 | Amicus Therapeutics, Inc. | Gene therapy constructs for the treatment of pompe disease |
WO2024163737A1 (en) | 2023-02-02 | 2024-08-08 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta 1 deficiency |
WO2024163560A1 (en) | 2023-02-01 | 2024-08-08 | Sarepta Therapeutics, Inc. | Raav production methods |
WO2024168276A2 (en) | 2023-02-09 | 2024-08-15 | Cargo Therapeutics, Inc. | Compositions and methods for immunotherapies |
US12071625B2 (en) | 2014-11-14 | 2024-08-27 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5843742A (en) * | 1994-12-16 | 1998-12-01 | Avigen Incorporated | Adeno-associated derived vector systems for gene delivery and integration into target cells |
CN113924115A (en) * | 2019-01-31 | 2022-01-11 | 俄勒冈健康与科学大学 | Methods for AAV capsids using transcription-dependent directed evolution |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994013788A1 (en) * | 1992-12-04 | 1994-06-23 | University Of Pittsburgh | Recombinant viral vector system |
WO1995013392A1 (en) * | 1993-11-09 | 1995-05-18 | Medical College Of Ohio | Stable cell lines capable of expressing the adeno-associated virus replication gene |
WO1995013365A1 (en) * | 1993-11-09 | 1995-05-18 | Targeted Genetics Corporation | Generation of high titers of recombinant aav vectors |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5173414A (en) * | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
-
1995
- 1995-12-06 EP EP95944069A patent/EP0796339A1/en not_active Withdrawn
- 1995-12-06 CA CA 2207927 patent/CA2207927A1/en not_active Abandoned
- 1995-12-06 AU AU45963/96A patent/AU707866B2/en not_active Ceased
- 1995-12-06 JP JP8517764A patent/JPH10511264A/en not_active Ceased
- 1995-12-06 WO PCT/US1995/015892 patent/WO1996017947A1/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994013788A1 (en) * | 1992-12-04 | 1994-06-23 | University Of Pittsburgh | Recombinant viral vector system |
WO1995013392A1 (en) * | 1993-11-09 | 1995-05-18 | Medical College Of Ohio | Stable cell lines capable of expressing the adeno-associated virus replication gene |
WO1995013365A1 (en) * | 1993-11-09 | 1995-05-18 | Targeted Genetics Corporation | Generation of high titers of recombinant aav vectors |
Cited By (378)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6924128B2 (en) | 1994-12-06 | 2005-08-02 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant AAV vectors |
US7235236B2 (en) | 1995-02-28 | 2007-06-26 | The Regents Of The University Of California | Polynucleotide encoding human adenylylcyclase VI and uses thereof for enhancing cardiac function |
US6752987B1 (en) | 1995-02-28 | 2004-06-22 | The Regents Of The University Of California | Adenovirus encoding human adenylylcyclase (AC) VI |
US6174871B1 (en) | 1995-02-28 | 2001-01-16 | The Regents Of The University Of California | Gene therapies for enhancing cardiac function |
WO1997049824A1 (en) * | 1996-06-24 | 1997-12-31 | Medigene Ag | System for the production of aav vectors |
US6541012B2 (en) | 1996-06-24 | 2003-04-01 | Christoph Bogedain | System for the production of AAV vectors |
US6306830B1 (en) | 1996-09-05 | 2001-10-23 | The Regents Of The University Of California | Gene therapy for congestive heart failure |
WO1998010088A1 (en) * | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
AU722375B2 (en) * | 1996-09-06 | 2000-08-03 | Trustees Of The University Of Pennsylvania, The | Methods using cre-lox for production of recombinant adeno-associated viruses |
WO1998010086A1 (en) * | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Methods using cre-lox for production of recombinant adeno-associated viruses |
US5866552A (en) * | 1996-09-06 | 1999-02-02 | The Trustees Of The University Of Pennsylvania | Method for expressing a gene in the absence of an immune response |
US6274354B1 (en) | 1996-09-06 | 2001-08-14 | The Trustees Of The University Of Pennsylvania | Methods using cre-lox for production of recombinant adeno-associated viruses |
US6428988B1 (en) | 1996-09-06 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Methods using cre-lox for production of recombinant adeno-associated viruses |
US6326356B1 (en) | 1996-10-18 | 2001-12-04 | Board Of Regents, The University Of Texas System | Suppression of neu overexpression using a mini-E1A gene |
US6197754B1 (en) | 1996-10-18 | 2001-03-06 | Board Of Regents, The University Of Texas System | Suppression of tumor growth by a mini-E1A gene |
WO1998027207A1 (en) * | 1996-12-18 | 1998-06-25 | Targeted Genetics Corporation | Recombinase-activatable aav packaging cassettes for use in the production of aav vectors |
US6541258B2 (en) | 1996-12-18 | 2003-04-01 | Targeted Genetics Corporation | AAV split-packaging genes and cell lines comprising such genes for use in the production of recombinant AAV vectors |
US6294370B1 (en) | 1997-06-24 | 2001-09-25 | Medigene Ag | System for the production of AAV vectors |
EP1944362A2 (en) | 1997-09-05 | 2008-07-16 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of recombinant AAV vectors |
EP2325299A2 (en) | 1997-09-05 | 2011-05-25 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of recombinant AAV vectors |
US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US6995006B2 (en) | 1997-09-05 | 2006-02-07 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US6989264B2 (en) | 1997-09-05 | 2006-01-24 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US6482634B1 (en) | 1997-09-19 | 2002-11-19 | The Trustees Of The University Of Pennsylvania | Methods and vector constructs useful for production of recombinant AAV |
US7238526B2 (en) | 1997-09-19 | 2007-07-03 | The Trustees Of The University Of Pennsylvania | Methods and cell line useful for production of recombinant adeno-associated viruses |
US6475769B1 (en) | 1997-09-19 | 2002-11-05 | The Trustees Of The University Of Pennsylvania | Methods and cell line useful for production of recombinant adeno-associated viruses |
WO1999014354A1 (en) * | 1997-09-19 | 1999-03-25 | The Trustees Of The University Of The Pennsylvania | Methods and vector constructs useful for production of recombinant aav |
WO1999015685A1 (en) * | 1997-09-19 | 1999-04-01 | The Trustees Of The University Of Pennsylvania | Methods and cell line useful for production of recombinant adeno-associated viruses |
US6943019B2 (en) | 1997-09-19 | 2005-09-13 | The Trustees Of The University Of Pennsylvania | Methods and vector constructs useful for production of recombinant AAV |
US6936466B2 (en) | 1997-10-21 | 2005-08-30 | Targeted Genetics Corporation | Transcriptionally-activated AAV inverted terminal repeats (ITRs) for use with recombinant AAV vectors |
US6642051B1 (en) | 1997-10-21 | 2003-11-04 | Targeted Genetics Corporation | Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors |
US6346415B1 (en) | 1997-10-21 | 2002-02-12 | Targeted Genetics Corporation | Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors |
AU733978B2 (en) * | 1997-11-21 | 2001-05-31 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Hormone-dependent forms of the adeno-associated virus, rep proteins, DNA sequences coding for them, vectors containing them, and regulatory methods of their intracellular activity |
WO1999027110A1 (en) * | 1997-11-21 | 1999-06-03 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Hormone-dependent forms of the adeno-associated virus, rep proteins, dna sequences coding for them, vectors containing them, and regulatory methods of their intracellular activity |
US6753419B1 (en) | 1997-11-21 | 2004-06-22 | Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | DNA molecules encoding hormone-dependent forms of the adeno-associated virus rep proteins |
WO1999061641A1 (en) * | 1998-05-22 | 1999-12-02 | University College London | Aav-vector production |
EP1930418A1 (en) | 1998-09-04 | 2008-06-11 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
EP2942393A1 (en) | 1998-09-04 | 2015-11-11 | Genzyme Corporation | Methods for generating high titer helper-free preparations of released recombinant aav vectors |
DE19905501B4 (en) * | 1999-02-10 | 2005-05-19 | MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie | A method of producing a recombinant adeno-associated virus, suitable compositions therefor, and use for the manufacture of a medicament |
US6846665B1 (en) | 1999-02-10 | 2005-01-25 | Medigene Aktiengesellschaft | Method of producing a recombinant adeno-associated virus, suitable means for producing the same and use thereof for producing a medicament |
US6893865B1 (en) | 1999-04-28 | 2005-05-17 | Targeted Genetics Corporation | Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles |
US6793926B1 (en) | 1999-05-27 | 2004-09-21 | Genovo, Inc. | Methods for production of a recombinant adeno-associated virus |
EP1939300A1 (en) | 1999-05-28 | 2008-07-02 | Targeted Genetics Corporation | Methods and compositions for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders |
US6537540B1 (en) | 1999-05-28 | 2003-03-25 | Targeted Genetics Corporation | Methods and composition for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders |
EP1916258A2 (en) | 1999-08-09 | 2008-04-30 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs |
US6596535B1 (en) | 1999-08-09 | 2003-07-22 | Targeted Genetics Corporation | Metabolically activated recombinant viral vectors and methods for the preparation and use |
US7125717B2 (en) | 1999-08-09 | 2006-10-24 | Targeted Genetics Corporation | Metabolically activated recombinant viral vectors and methods for their preparation and use |
US7785888B2 (en) | 1999-08-09 | 2010-08-31 | Genzyme Corporation | Metabolically activated recombinant viral vectors and methods for their preparation and use |
US7846729B2 (en) | 1999-08-09 | 2010-12-07 | Genzyme Corporation | Metabolically activated recombinant viral vectors and methods for their preparation and use |
US8093054B2 (en) | 1999-08-09 | 2012-01-10 | Genzyme Corporation | Metabolically activated recombinant viral vectors and methods for their preparation and use |
EP2369002A1 (en) | 1999-08-09 | 2011-09-28 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs |
US7115391B1 (en) | 1999-10-01 | 2006-10-03 | Genovo, Inc. | Production of recombinant AAV using adenovirus comprising AAV rep/cap genes |
US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
US7271002B2 (en) | 2001-11-09 | 2007-09-18 | United States Of America, Represented By The Secretary, Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
US9873868B2 (en) | 2003-01-22 | 2018-01-23 | Duke University | Constructs for expressing lysosomal polypeptides |
WO2005077091A2 (en) | 2004-02-10 | 2005-08-25 | Trustees Of Dartmouth College | Nicotinamide riboside kinase compositions and methods for using the same |
EP2311966A2 (en) | 2005-10-20 | 2011-04-20 | Amsterdam Molecular Therapeutics B.V. | Improved AAV vectors produced in insect cells |
EP2311967A2 (en) | 2005-10-20 | 2011-04-20 | Amsterdam Molecular Therapeutics B.V. | Improved AAV vectors produced in insect cells |
EP3705577A1 (en) | 2006-06-21 | 2020-09-09 | uniQure IP B.V. | Aav vectors with improved rep coding sequences for production in insect cells |
EP3023500A1 (en) | 2006-06-21 | 2016-05-25 | UniQure IP B.V. | Insect cells for the production of aav vectors |
WO2007148971A2 (en) | 2006-06-21 | 2007-12-27 | Amsterdam Molecular Therapeutics B.V. | Vectors with modified initiation codon for the translation of aav-rep78 useful for production of aav in insect cells |
US9879282B2 (en) | 2006-08-24 | 2018-01-30 | Virovek, Inc. | Expression in insect cells of genes with overlapping open reading frames, methods and compositions therefor |
US8945918B2 (en) | 2006-08-24 | 2015-02-03 | Virovek, Inc. | Expression in insect cells of genes with overlapping open reading frames, methods and compositions therefor |
US9879279B2 (en) | 2006-08-24 | 2018-01-30 | Virovek, Inc. | Expression in insect cells of genes with overlapping open reading frames, methods and compositions therefor |
EP2679237A1 (en) | 2006-11-29 | 2014-01-01 | Nationwide Children's Hospital | Myostatin inhibition for enhancing muscle and/or improving muscle function |
WO2008067480A2 (en) | 2006-11-29 | 2008-06-05 | Nationwide Children's Hospital | Myostatin inhibition for enhancing muscle and/or improving muscle function |
US8895309B2 (en) | 2006-11-29 | 2014-11-25 | Nationwide Children's Hospital | Myostatin inhibition for enhancing muscle and/or improving muscle function |
US11219696B2 (en) | 2008-12-19 | 2022-01-11 | Nationwide Children's Hospital | Delivery of polynucleotides using recombinant AAV9 |
US9415121B2 (en) | 2008-12-19 | 2016-08-16 | Nationwide Children's Hospital | Delivery of MECP2 polynucleotide using recombinant AAV9 |
WO2010109053A1 (en) | 2009-03-27 | 2010-09-30 | Proyeto De Biomedicina Cima, S.L. | Methods and compositions for the treatment of cirrhosis and liver fibrosis |
US11975043B2 (en) | 2009-05-02 | 2024-05-07 | Genzyme Corporation | Gene therapy for neurodegenerative disorders |
US9415119B2 (en) | 2009-05-02 | 2016-08-16 | Genzyme Corporation | Gene therapy for neurodegenerative disorders |
US10369193B2 (en) | 2009-05-02 | 2019-08-06 | Genzyme Corporation | Gene therapy for neurodegenerative disorders |
US11911440B2 (en) | 2009-05-02 | 2024-02-27 | Genzyme Corporation | Gene therapy for neurodegenerative disorders |
WO2011054994A1 (en) | 2009-11-05 | 2011-05-12 | Proyecto De Biomedicina Cima, S.L. | Regulated expression systems |
EP2767298A2 (en) | 2010-11-23 | 2014-08-20 | Presage Biosciences, Inc. | Therapeutic methods and compositions for solid delivery |
US10214730B2 (en) | 2011-04-19 | 2019-02-26 | The Research Foundation For The State University Of New York | Adeno-associated-virus Rep sequences, vectors and viruses |
US11091760B2 (en) | 2011-04-21 | 2021-08-17 | Nationwide Children's Hospital, Inc. | Recombinant virus products and methods for inhibition of expression of myotilin |
US9133482B2 (en) | 2011-04-21 | 2015-09-15 | Nationwide Children's Hospital, Inc. | Recombinant virus products and methods for inhibition of expression of myotilin |
US10196636B2 (en) | 2011-04-21 | 2019-02-05 | Nationwide Children's Hospital, Inc. | Recombinant virus products and methods for inhibition of expression of myotilin |
EP3495472A1 (en) | 2011-04-21 | 2019-06-12 | Nationwide Children's Hospital, Inc. | Recombinant virus products and methods for inhibition of expression of myotilin |
US11590210B2 (en) | 2011-06-08 | 2023-02-28 | Nationwide Children's Hospital, Inc. | Methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders |
US9469851B2 (en) | 2011-07-25 | 2016-10-18 | Nationwide Children's Hospital, Inc. | Recombinant virus products and methods for inhibition of expression of DUX4 |
US10301649B2 (en) | 2011-07-25 | 2019-05-28 | Nationwide Children's Hospital, Inc. | Recombinant virus products and methods for inhibition of expression of DUX4 |
US11802291B2 (en) | 2011-07-25 | 2023-10-31 | Research Institute At Nationwide Children's Hospital | Recombinant virus products and methods for inhibition of expression of DUX4 |
EP3290055A2 (en) | 2011-07-25 | 2018-03-07 | Nationwide Children's Hospital, Inc. | Recombinant virus products and methods for inhibition of expression of dux4 |
US10105453B2 (en) | 2011-11-23 | 2018-10-23 | Nationwide Children's Hospital, Inc. | Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides |
US9434928B2 (en) | 2011-11-23 | 2016-09-06 | Nationwide Children's Hospital, Inc. | Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides |
WO2013164793A2 (en) | 2012-05-04 | 2013-11-07 | Novartis Ag | Viral vectors for the treatment of retinal dystrophy |
EP3326655A1 (en) | 2012-05-04 | 2018-05-30 | Novartis AG | Aav viral vectors for the treatment of rlbp1-associated retinal dystrophy |
US11311634B2 (en) | 2012-08-01 | 2022-04-26 | Nationwide Children's Hospital | Intrathecal delivery of recombinant Adeno-associated virus 9 |
US11738094B2 (en) | 2012-08-01 | 2023-08-29 | Nationwide Children's Hospital | Intrathecal delivery of recombinant adeno-associated virus 9 |
EP3415167A1 (en) | 2012-08-01 | 2018-12-19 | Nationwide Children's Hospital | Intrathecal delivery of recombinant adeno-associated virus 9 |
US11040116B2 (en) | 2012-08-01 | 2021-06-22 | Nationwide Children's Hospital | Intrathecal delivery of recombinant adeno-associated virus 9 |
US11413357B2 (en) | 2012-08-01 | 2022-08-16 | Nationwide Children's Hospital | Intrathecal delivery of recombinant adeno-associated virus 9 |
EP3769789A1 (en) | 2012-08-01 | 2021-01-27 | Nationwide Children's Hospital | Intrathecal delivery of recombinant adeno-associated virus 9 |
US11730829B2 (en) | 2012-08-01 | 2023-08-22 | Nationwide Children's Hospital | Intrathecal delivery of recombinant adeno-associated virus 9 |
US9539307B2 (en) | 2012-09-17 | 2017-01-10 | The Research Institute At Nationwide Children's Hospital | Compositions and methods for treating amyotrophic lateral sclerosis |
WO2014165349A1 (en) | 2013-04-04 | 2014-10-09 | Trustees Of Dartmouth College | Compositions and methods for in vivo excision of hiv-1 proviral dna |
WO2014168953A1 (en) | 2013-04-08 | 2014-10-16 | University Of Iowa Research Foundation | Chimeric adeno-associated virus/ bocavirus parvovirus vector |
EP3461838A1 (en) | 2013-04-20 | 2019-04-03 | Research Institute at Nationwide Children's Hospital | Recombinant adeno-associated virus delivery of exon 2-targeted u7snrna polynucleotide constructs |
US9862945B2 (en) | 2013-04-20 | 2018-01-09 | Research Institute At Nationwide Children's Hospital | Recombinant adeno-associated virus delivery of exon 2-targeted U7SNRNA polynucleotide constructs |
WO2014172669A1 (en) | 2013-04-20 | 2014-10-23 | Research Institute At Nationwide Children's Hospital | Recombinant adeno-associated virus delivery of exon 2-targeted u7snrna polynucleotide constructs |
US11230707B2 (en) | 2013-04-20 | 2022-01-25 | Research Institute At Nationwide Children's Hospital | Recombinant adeno-associated virus delivery of exon 2-targeted U7SNRNA polynucleotide constructs |
EP3622821A1 (en) | 2013-05-15 | 2020-03-18 | Regents of the University of Minnesota | Adeno-associated virus mediated gene transfer to the central nervous system |
US10793861B2 (en) | 2013-08-27 | 2020-10-06 | Research Institute At Nationwide Children's Hospital | Products and methods for treatment of familial amyotrophic lateral sclerosis |
EP4219727A2 (en) | 2013-08-27 | 2023-08-02 | Research Institute at Nationwide Children's Hospital | Products and methods for treatment of amyotrophic lateral sclerosis |
EP3702466A1 (en) | 2013-08-27 | 2020-09-02 | Research Institute at Nationwide Children's Hospital | Products and methods for treatment of amyotrophic lateral sclerosis |
US9725719B2 (en) | 2013-11-05 | 2017-08-08 | The Research Institute At Nationwide Children's Hospital | Compositions and methods for inhibiting NF-κB and SOD-1 to treat amyotrophic lateral sclerosis |
US11344630B2 (en) | 2014-03-18 | 2022-05-31 | Washington University | Methods and compositions for red-shifted chromophore substitution for optogenetic applications |
US10047130B2 (en) | 2014-03-18 | 2018-08-14 | Washington University | Methods and compositions for red-shifted chromophore substitution for optogenetic applications |
US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
US11053494B2 (en) | 2014-08-09 | 2021-07-06 | Research Institute At Nationwide Children's Hospital | Methods and materials for activating an internal ribosome entry site in exon 5 of the DMD gene |
EP3572516A1 (en) | 2014-08-09 | 2019-11-27 | The Research Institute at Nationwide Children's Hospital | Methods and materials for activating an internal ribosome entry site in exon 5 of the dmd gene |
WO2016057975A2 (en) | 2014-10-10 | 2016-04-14 | Research Institute At Nationwide Children's Hospital | Guided injections for aav gene transfer to muscle |
US10842886B2 (en) | 2014-10-10 | 2020-11-24 | Research Institute At Nationwide Children's Hospital | Guided injections for AAV gene transfer to muscle |
EP3690024A1 (en) | 2014-11-05 | 2020-08-05 | The Research Institute at Nationwide Children's Hospital | Methods and materials for producing recombinant viruses in eukaryotic microalgae |
US12077748B2 (en) | 2014-11-05 | 2024-09-03 | The Research Institute At Nationwide Children's Hospital | Methods and materials for producing recombinant viruses in eukaryotic microalgae |
US10907130B2 (en) | 2014-11-05 | 2021-02-02 | Research Institute At Nationwide Children's Hospital | Methods and materials for producing recombinant viruses in eukaryotic microalgae |
US12071625B2 (en) | 2014-11-14 | 2024-08-27 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
WO2016122791A1 (en) | 2015-01-30 | 2016-08-04 | The Regents Of The University Of California | Spinal subpial gene delivery system |
WO2016126993A1 (en) | 2015-02-04 | 2016-08-11 | Washington University | Anti-tau constructs |
EP4059961A2 (en) | 2015-02-04 | 2022-09-21 | Washington University | Anti-tau constructs |
WO2016135558A2 (en) | 2015-02-23 | 2016-09-01 | Crispr Therapeutics Ag | Materials and methods for treatment of hemoglobinopathies |
EP4000631A1 (en) | 2015-05-15 | 2022-05-25 | REGENXBIO Inc. | Adeno-associated for therapeutic delivery to central nervous system |
WO2016187017A1 (en) | 2015-05-15 | 2016-11-24 | Mcivor R Scott | Adeno-associated for therapeutic delivery to central nervous system |
US10017832B2 (en) | 2015-08-25 | 2018-07-10 | Washington University | Compositions and methods for site specific recombination at asymmetric sites |
US10980897B2 (en) | 2015-09-17 | 2021-04-20 | Research Institute At Nationwide Children's Hospital | Methods and materials for GALGT2 gene therapy |
WO2017064546A1 (en) | 2015-09-24 | 2017-04-20 | Crispr Therapeutics Ag | Novel family of rna-programmable endonucleases and their uses in genome editing and other applications |
WO2017075335A1 (en) | 2015-10-28 | 2017-05-04 | Voyager Therapeutics, Inc. | Regulatable expression using adeno-associated virus (aav) |
WO2017072590A1 (en) | 2015-10-28 | 2017-05-04 | Crispr Therapeutics Ag | Materials and methods for treatment of duchenne muscular dystrophy |
EP4279084A1 (en) | 2015-10-28 | 2023-11-22 | Vertex Pharmaceuticals Inc. | Materials and methods for treatment of duchenne muscular dystrophy |
US11866727B2 (en) | 2015-11-06 | 2024-01-09 | Crispr Therapeutics Ag | Materials and methods for treatment of glycogen storage disease type 1A |
WO2017077386A1 (en) | 2015-11-06 | 2017-05-11 | Crispr Therapeutics Ag | Materials and methods for treatment of glycogen storage disease type 1a |
US11617783B2 (en) | 2015-11-16 | 2023-04-04 | Research Institute At Nationwide Children's Hospital | Repairing a mutant human titin gene using CRISPR technology |
EP3967758A1 (en) | 2015-12-01 | 2022-03-16 | CRISPR Therapeutics AG | Materials and methods for treatment of alpha-1 antitrypsin deficiency |
US11851653B2 (en) | 2015-12-01 | 2023-12-26 | Crispr Therapeutics Ag | Materials and methods for treatment of alpha-1 antitrypsin deficiency |
WO2017093804A2 (en) | 2015-12-01 | 2017-06-08 | Crispr Therapeutics Ag | Materials and methods for treatment of alpha-1 antitrypsin deficiency |
WO2017109757A1 (en) | 2015-12-23 | 2017-06-29 | Crispr Therapeutics Ag | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration |
US11938193B2 (en) | 2016-01-08 | 2024-03-26 | Washington University | Compositions comprising chemerin and methods of use thereof |
WO2017134529A1 (en) | 2016-02-02 | 2017-08-10 | Crispr Therapeutics Ag | Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome |
WO2017139381A1 (en) | 2016-02-08 | 2017-08-17 | University Of Iowa Research Foundation | Methods to produce chimeric adeno-associated virus/bocavirus parvovirus |
WO2017141109A1 (en) | 2016-02-18 | 2017-08-24 | Crispr Therapeutics Ag | Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome |
US11066456B2 (en) | 2016-02-25 | 2021-07-20 | Washington University | Compositions comprising TREM2 and methods of use thereof |
US12084658B2 (en) | 2016-02-26 | 2024-09-10 | Research Institute At Nationwide Children's Hospital | Recombinant virus products and methods for inducing DUX4 exon skipping |
US11180755B2 (en) | 2016-02-26 | 2021-11-23 | Research Institute At Nationwide Children's Hospital | Recombinant virus products and methods for inducing DUX4 exon skipping |
WO2017147467A1 (en) | 2016-02-26 | 2017-08-31 | Research Institute At Nationwide Children's Hospital | Recombinant virus products and methods for inducing dux4 exon skipping |
WO2017158422A1 (en) | 2016-03-16 | 2017-09-21 | Crispr Therapeutics Ag | Materials and methods for treatment of hereditary haemochromatosis |
US11083799B2 (en) | 2016-03-16 | 2021-08-10 | Crispr Therapeutics Ag | Materials and methods for treatment of hereditary haemochromatosis |
WO2017172772A1 (en) | 2016-03-28 | 2017-10-05 | Dimension Therapeutics | Methods of heat inactivation of adenovirus |
US11944658B2 (en) | 2016-03-28 | 2024-04-02 | Ultragenyx Pharmaceutical Inc. | Methods of heat inactivation of adenovirus |
US11013774B2 (en) | 2016-03-28 | 2021-05-25 | Ultragenyx Pharmaceutical Inc. | Methods of heat inactivation of adenovirus |
WO2017172606A1 (en) | 2016-03-28 | 2017-10-05 | The Regents Of The University Of California | Method and composition for treating neuronal hyper-excitability |
EP4159867A1 (en) | 2016-03-28 | 2023-04-05 | Ultragenyx Pharmaceutical Inc. | Methods of heat inactivation of adenovirus |
EP4335502A2 (en) | 2016-04-02 | 2024-03-13 | Research Institute at Nationwide Children's Hospital | Modified u6 promoter system for tissue specific expression |
US11345913B2 (en) | 2016-04-02 | 2022-05-31 | Research Institute At Nationwide Children's Hospital | Modified U6 promoter system for tissue specific expression |
WO2017173411A1 (en) | 2016-04-02 | 2017-10-05 | Research Institute At Nation Wide Children's Hospital | Modified u6 promoter system for tissue specific expression |
US11939579B2 (en) | 2016-04-02 | 2024-03-26 | Research Institute At Nationwide Children's Hospital | Modified U6 promoter system for tissue specific expression |
EP4407035A2 (en) | 2016-04-15 | 2024-07-31 | Research Institute at Nationwide Children's Hospital | Adeno-associated virus vector delivery of b-sarcoglycan and microrna-29 and the treatment of muscular dystrophy |
WO2017181015A1 (en) | 2016-04-15 | 2017-10-19 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery of micro-dystrophin to treat muscular dystrophy |
US11406717B2 (en) | 2016-04-15 | 2022-08-09 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery of microRNA-29 and micro-dystrophin to treat muscular dystrophy |
WO2017181011A1 (en) | 2016-04-15 | 2017-10-19 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery of microrna-29 to treat muscular dystrophy |
WO2017180976A1 (en) | 2016-04-15 | 2017-10-19 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery of b-sarcoglycan and microrna-29 and the treatment of muscular dystrophy |
WO2017181014A1 (en) | 2016-04-15 | 2017-10-19 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery of microrna-29 and micro-dystrophin to treat muscular dystrophy |
US11358993B2 (en) | 2016-04-15 | 2022-06-14 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery of B-sarcoglycan and microrna-29 and the treatment of muscular dystrophy |
US11723986B2 (en) | 2016-04-15 | 2023-08-15 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery of micro-dystrophin to treat muscular dystrophy |
EP4410979A2 (en) | 2016-04-15 | 2024-08-07 | Research Institute at Nationwide Children's Hospital | Adeno-associated virus vector delivery of microrna-29 and micro-dystrophin to treat muscular dystrophy |
US11298429B2 (en) | 2016-04-15 | 2022-04-12 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery of microrna-29 to treat muscular dystrophy |
EP4424829A2 (en) | 2016-04-18 | 2024-09-04 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of hemoglobinopathies |
WO2017182881A2 (en) | 2016-04-18 | 2017-10-26 | Crispr Therapeutics Ag | Materials and methods for treatment of hemoglobinopathies |
US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
WO2017191503A1 (en) | 2016-05-05 | 2017-11-09 | Crispr Therapeutics Ag | Materials and methods for treatment of hemoglobinopathies |
US11951121B2 (en) | 2016-05-18 | 2024-04-09 | Voyager Therapeutics, Inc. | Compositions and methods for treating Huntington's disease |
US10584337B2 (en) | 2016-05-18 | 2020-03-10 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
US12084659B2 (en) | 2016-05-18 | 2024-09-10 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
US11193129B2 (en) | 2016-05-18 | 2021-12-07 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
US11174469B2 (en) | 2016-06-29 | 2021-11-16 | Crispr Therapeutics Ag | Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders |
WO2018002762A1 (en) | 2016-06-29 | 2018-01-04 | Crispr Therapeutics Ag | Materials and methods for treatment of amyotrophic lateral sclerosis (als) and other related disorders |
WO2018002812A1 (en) | 2016-06-29 | 2018-01-04 | Crispr Therapeutics Ag | Materials and methods for treatment of myotonic dystrophy type 1 (dm1) and other related disorders |
US11564997B2 (en) | 2016-06-29 | 2023-01-31 | Crispr Therapeutics Ag | Materials and methods for treatment of friedreich ataxia and other related disorders |
WO2018002783A1 (en) | 2016-06-29 | 2018-01-04 | Crispr Therapeutics Ag | Materials and methods for treatment of friedreich ataxia and other related disorders |
US11459587B2 (en) | 2016-07-06 | 2022-10-04 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of pain related disorders |
US11801313B2 (en) | 2016-07-06 | 2023-10-31 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of pain related disorders |
WO2018007980A1 (en) | 2016-07-06 | 2018-01-11 | Crispr Therapeutics Ag | Materials and methods for treatment of pain related disorders |
WO2018007976A1 (en) | 2016-07-06 | 2018-01-11 | Crispr Therapeutics Ag | Materials and methods for treatment of pain related disorders |
WO2018007871A1 (en) | 2016-07-08 | 2018-01-11 | Crispr Therapeutics Ag | Materials and methods for treatment of transthyretin amyloidosis |
WO2018020323A2 (en) | 2016-07-25 | 2018-02-01 | Crispr Therapeutics Ag | Materials and methods for treatment of fatty acid disorders |
WO2018071817A1 (en) | 2016-10-14 | 2018-04-19 | Dimension Therapeutics | Use of tonicifying agents to enhance recombinant adeno-associated virus yield |
US11795473B2 (en) | 2016-10-14 | 2023-10-24 | Ultragenyx Pharmaceutical Inc. | Use of tonicifying agents to enhance recombinant adeno-associated virus yield |
WO2018093925A1 (en) | 2016-11-15 | 2018-05-24 | Laoharawee Kanut | Method for improving neurological function in mpsi and mpsii and other neurological disorders |
WO2018094251A1 (en) | 2016-11-17 | 2018-05-24 | Kaspar Brian K | Intrathecal delivery of recombinant adeno-associated virus encoding methyl-cpg binding protein 2 |
US11583564B2 (en) | 2016-11-17 | 2023-02-21 | Nationwide Children's Hospital, Inc. | Intrathecal delivery of recombinant adeno-associated virus encoding Methyl-CpG binding protein 2 |
US11753460B2 (en) | 2016-12-13 | 2023-09-12 | Seattle Children's Hospital | Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo |
WO2018132747A1 (en) | 2017-01-13 | 2018-07-19 | University Of Iowa Research Foundation | Bocaparvovirus small noncoding rna and uses thereof |
US11407997B2 (en) | 2017-02-22 | 2022-08-09 | Crispr Therapeutics Ag | Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders |
WO2018154462A2 (en) | 2017-02-22 | 2018-08-30 | Crispr Therapeutics Ag | Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders |
WO2018154418A1 (en) | 2017-02-22 | 2018-08-30 | Crispr Therapeutics Ag | Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders |
WO2018154387A1 (en) | 2017-02-22 | 2018-08-30 | Crispr Therapeutics Ag | Compositions and methods for gene editing |
US11559588B2 (en) | 2017-02-22 | 2023-01-24 | Crispr Therapeutics Ag | Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disorders |
US11920148B2 (en) | 2017-02-22 | 2024-03-05 | Crispr Therapeutics Ag | Compositions and methods for gene editing |
EP4245852A2 (en) | 2017-03-17 | 2023-09-20 | Research Institute at Nationwide Children's Hospital | Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy |
WO2019012336A2 (en) | 2017-03-17 | 2019-01-17 | Newcastle University | Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy |
WO2018170408A1 (en) | 2017-03-17 | 2018-09-20 | Research Institute At Nationwide Children's Hospital, Inc. | Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy |
US11338045B2 (en) | 2017-03-17 | 2022-05-24 | Newcastle University | Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy |
US11898170B2 (en) | 2017-03-22 | 2024-02-13 | Ultragenyx Pharmaceutical Inc. | Cell culture methods involving HDAC inhibitors or rep proteins |
US11603542B2 (en) | 2017-05-05 | 2023-03-14 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
US11752181B2 (en) | 2017-05-05 | 2023-09-12 | Voyager Therapeutics, Inc. | Compositions and methods of treating Huntington's disease |
WO2019097305A2 (en) | 2017-05-12 | 2019-05-23 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
WO2019011817A1 (en) | 2017-07-08 | 2019-01-17 | Genethon | Treatment of spinal muscular atrophy |
US11497576B2 (en) | 2017-07-17 | 2022-11-15 | Voyager Therapeutics, Inc. | Trajectory array guide system |
US11512327B2 (en) | 2017-08-03 | 2022-11-29 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of AAV |
EP3808849A1 (en) | 2017-08-03 | 2021-04-21 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
WO2019028306A2 (en) | 2017-08-03 | 2019-02-07 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
WO2019067982A2 (en) | 2017-09-29 | 2019-04-04 | Massachusetts Eye And Ear Infirmary | Production of adeno-associated viruses in insect cells |
US11931375B2 (en) | 2017-10-16 | 2024-03-19 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (ALS) |
EP4124658A2 (en) | 2017-10-16 | 2023-02-01 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
WO2019079240A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
US11434502B2 (en) | 2017-10-16 | 2022-09-06 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (ALS) |
WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
WO2019079527A1 (en) | 2017-10-17 | 2019-04-25 | Casebia Therapeutics Limited Liability Partnership | Compositions and methods for gene editing for hemophilia a |
US11534501B2 (en) | 2017-10-18 | 2022-12-27 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy |
US11926653B2 (en) | 2017-10-20 | 2024-03-12 | Research Institute At Nationwide Children's Hospital | Methods and materials for NT-3 gene therapy |
WO2019081982A1 (en) | 2017-10-26 | 2019-05-02 | Crispr Therapeutics Ag | Materials and methods for treatment of hemoglobinopathies |
WO2019094253A1 (en) | 2017-11-08 | 2019-05-16 | Avexis Inc. | Means and method for preparing viral vectors and uses of same |
WO2019092505A1 (en) | 2017-11-09 | 2019-05-16 | Casebia Therapeutics Llp | Self-inactivating (sin) crispr/cas or crispr/cpf1 systems and uses thereof |
WO2019092507A2 (en) | 2017-11-09 | 2019-05-16 | Crispr Therapeutics Ag | Crispr/cas systems for treatment of dmd |
WO2019102381A1 (en) | 2017-11-21 | 2019-05-31 | Casebia Therapeutics Llp | Materials and methods for treatment of autosomal dominant retinitis pigmentosa |
WO2019118935A1 (en) | 2017-12-14 | 2019-06-20 | Casebia Therapeutics Limited Liability Partnership | Novel rna-programmable endonuclease systems and their use in genome editing and other applications |
WO2019123430A1 (en) | 2017-12-21 | 2019-06-27 | Casebia Therapeutics Llp | Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp) |
WO2019123429A1 (en) | 2017-12-21 | 2019-06-27 | Casebia Therapeutics Llp | Materials and methods for treatment of usher syndrome type 2a |
WO2019140330A1 (en) | 2018-01-12 | 2019-07-18 | Casebia Therapeutics Limited Liability Partnership | Compositions and methods for gene editing by targeting transferrin |
WO2019150196A1 (en) | 2018-02-05 | 2019-08-08 | Crispr Therapeutics Ag | Materials and methods for treatment of hemoglobinopathies |
WO2019150203A1 (en) | 2018-02-05 | 2019-08-08 | Crispr Therapeutics Ag | Materials and methods for treatment of hemoglobinopathies |
WO2019161310A1 (en) | 2018-02-16 | 2019-08-22 | Casebia Therapeutics Limited Liability Partnership | Compositions and methods for gene editing by targeting fibrinogen-alpha |
WO2019183150A1 (en) | 2018-03-19 | 2019-09-26 | Casebia Therapeutics Limited Liability Partnership | Novel rna-programmable endonuclease systems and uses thereof |
US12037707B2 (en) | 2018-04-05 | 2024-07-16 | Massachusetts Eye And Ear Infirmary | Methods of making and using combinatorial barcoded nucleic acid libraries having defined variation |
WO2019204668A1 (en) | 2018-04-18 | 2019-10-24 | Casebia Therapeutics Limited Liability Partnership | Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease |
WO2019210137A1 (en) | 2018-04-27 | 2019-10-31 | Voyager Therapeutics, Inc. | Methods for measuring the potency of aadc viral vectors |
US11987804B2 (en) | 2018-04-27 | 2024-05-21 | Seattle Children's Hospital | Rapamycin resistant cells |
WO2019222328A1 (en) | 2018-05-15 | 2019-11-21 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of parkinson's disease |
WO2019222329A1 (en) | 2018-05-15 | 2019-11-21 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
WO2019222444A2 (en) | 2018-05-16 | 2019-11-21 | Voyager Therapeutics, Inc. | Directed evolution |
WO2019222441A1 (en) | 2018-05-16 | 2019-11-21 | Voyager Therapeutics, Inc. | Aav serotypes for brain specific payload delivery |
WO2019236949A1 (en) | 2018-06-08 | 2019-12-12 | Avexis Inc. | Cell-based assay for measuring drug product potency |
WO2019238692A1 (en) | 2018-06-12 | 2019-12-19 | The University Of Bristol | Materials and methods for modulating intraocular and intracranial pressure |
WO2019241486A1 (en) | 2018-06-13 | 2019-12-19 | Voyager Therapeutics, Inc. | Engineered 5' untranslated regions (5' utr) for aav production |
WO2019245973A1 (en) | 2018-06-18 | 2019-12-26 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy |
WO2019246125A1 (en) | 2018-06-18 | 2019-12-26 | Research Institute At Nationwide Children's Hospital | Recombinant adeno-associated virus products and methods for treating dystroglycanopathies and laminin-deficient muscular dystrophies |
WO2020006458A1 (en) | 2018-06-29 | 2020-01-02 | Research Institute At Nationwide Children's Hospital | Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a |
WO2020010042A1 (en) | 2018-07-02 | 2020-01-09 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord |
WO2020023612A1 (en) | 2018-07-24 | 2020-01-30 | Voyager Therapeutics, Inc. | Systems and methods for producing gene therapy formulations |
WO2020047268A1 (en) | 2018-08-29 | 2020-03-05 | Research Institute At Nationwide Children's Hospital | Products and methods for inhibition of expression of mutant gars protein |
WO2020069461A1 (en) | 2018-09-28 | 2020-04-02 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
WO2020072849A1 (en) | 2018-10-04 | 2020-04-09 | Voyager Therapeutics, Inc. | Methods for measuring the titer and potency of viral vector particles |
WO2020072844A1 (en) | 2018-10-05 | 2020-04-09 | Voyager Therapeutics, Inc. | Engineered nucleic acid constructs encoding aav production proteins |
WO2020077165A1 (en) | 2018-10-12 | 2020-04-16 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
WO2020081490A1 (en) | 2018-10-15 | 2020-04-23 | Voyager Therapeutics, Inc. | EXPRESSION VECTORS FOR LARGE-SCALE PRODUCTION OF rAAV IN THE BACULOVIRUS/Sf9 SYSTEM |
WO2020081843A1 (en) | 2018-10-17 | 2020-04-23 | Casebia Therapeutics Limited Liability Partnership | Compositions and methods for delivering transgenes |
WO2020113034A1 (en) | 2018-11-30 | 2020-06-04 | Avexis, Inc. | Aav viral vectors and uses thereof |
WO2020127813A1 (en) | 2018-12-21 | 2020-06-25 | Genethon | Expression cassettes for gene therapy vectors |
WO2020142479A1 (en) | 2018-12-31 | 2020-07-09 | Research Institute At Nationwide Children's Hospital | Dux4 rna silencing using rna targeting crispr-cas13b |
WO2020150556A1 (en) | 2019-01-18 | 2020-07-23 | Voyager Therapeutics, Inc. | Methods and systems for producing aav particles |
WO2020163300A1 (en) | 2019-02-04 | 2020-08-13 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus delivery of cln3 polynucleotide |
WO2020163299A1 (en) | 2019-02-04 | 2020-08-13 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus delivery of cln6 polynucleotide |
WO2020168362A1 (en) | 2019-02-15 | 2020-08-20 | Crispr Therapeutics Ag | Gene editing for hemophilia a with improved factor viii expression |
WO2020174369A2 (en) | 2019-02-25 | 2020-09-03 | Novartis Ag | Compositions and methods to treat bietti crystalline dystrophy |
WO2020174368A1 (en) | 2019-02-25 | 2020-09-03 | Novartis Ag | Compositions and methods to treat bietti crystalline dystrophy |
WO2020176614A1 (en) | 2019-02-26 | 2020-09-03 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery of b-sarcoglycan and the treatment of muscular dystrophy |
WO2020186059A2 (en) | 2019-03-12 | 2020-09-17 | Crispr Therapeutics Ag | Novel high fidelity rna-programmable endonuclease systems and uses thereof |
US12018288B2 (en) | 2019-04-12 | 2024-06-25 | Ultragenyx Pharmaceutical Inc. | Engineered producer cell lines and methods of making and using the same |
WO2020210507A1 (en) | 2019-04-12 | 2020-10-15 | Ultragenyx Pharmaceutical Inc. | Engineered producer cell lines and methods of making and using the same |
WO2020214737A1 (en) | 2019-04-15 | 2020-10-22 | Sanford Research | Gene therapy for treating or preventing visual effects in batten disease |
WO2020214672A1 (en) | 2019-04-15 | 2020-10-22 | University Of Iowa Research Foundation | Methods and compositions for transgene expression |
WO2020223274A1 (en) | 2019-04-29 | 2020-11-05 | Voyager Therapeutics, Inc. | SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS |
WO2020227515A1 (en) | 2019-05-07 | 2020-11-12 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
WO2020225606A1 (en) | 2019-05-08 | 2020-11-12 | Crispr Therapeutics Ag | Crispr/cas all-in-two vector systems for treatment of dmd |
WO2020236352A1 (en) | 2019-05-17 | 2020-11-26 | Research Institute At Nationwide Children's Hospital | Optimized gene therapy targeting retinal cells |
WO2020236351A1 (en) | 2019-05-17 | 2020-11-26 | Research Institute At Nationwide Children's Hospital | Improved delivery of gene therapy vectors to retinal cells using a glycoside hydrolase enzyme |
WO2020264254A1 (en) | 2019-06-28 | 2020-12-30 | Crispr Therapeutics Ag | Materials and methods for controlling gene editing |
WO2021014428A1 (en) | 2019-07-25 | 2021-01-28 | Novartis Ag | Regulatable expression systems |
WO2021030125A1 (en) | 2019-08-09 | 2021-02-18 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
EP4374880A2 (en) | 2019-08-21 | 2024-05-29 | Research Institute at Nationwide Children's Hospital | Adeno-associated virus vector delivery of alpha-sarcoglycan and the treatment of muscular dystrophy |
WO2021035120A1 (en) | 2019-08-21 | 2021-02-25 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery of alpha-sarcoglycan and the treatment of muscular dystrophy |
WO2021041485A1 (en) | 2019-08-26 | 2021-03-04 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
WO2021046155A1 (en) | 2019-09-03 | 2021-03-11 | Voyager Therapeutics, Inc. | Vectorized editing of nucleic acids to correct overt mutations |
WO2021072115A1 (en) | 2019-10-08 | 2021-04-15 | Regents Of The University Of Minnesota | Crispr-mediated human genome editing with vectors |
WO2021072129A2 (en) | 2019-10-08 | 2021-04-15 | Trustees Of Boston College | Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins |
WO2021077115A1 (en) | 2019-10-18 | 2021-04-22 | Research Institute At Nationwide Children's Hospital | Gene therapy targeting cochlear cells |
WO2021077101A1 (en) | 2019-10-18 | 2021-04-22 | Research Institute At Nationwide Children's Hospital | Materials and methods for the treatment of disorders associated mutations in the irf2bpl gene |
WO2021102435A1 (en) | 2019-11-22 | 2021-05-27 | Research Institute At Nationwide Children's Hospital | Materials and methods for treatment of disorders associated with the ighmbp2 gene |
WO2021127655A1 (en) | 2019-12-20 | 2021-06-24 | Research Institute At Nationwide Children's Hospital | Optimized gene therapy for targeting muscle in muscle diseases |
WO2021168124A1 (en) | 2020-02-18 | 2021-08-26 | Research Institute At Nationwide Children's Hospital | Aav-mediated targeting of mirna in the treatment of x-linked disorders |
WO2022074464A2 (en) | 2020-03-05 | 2022-04-14 | Neotx Therapeutics Ltd. | Methods and compositions for treating cancer with immune cells |
WO2021188449A1 (en) | 2020-03-16 | 2021-09-23 | Ultragenyx Pharmaceutical Inc. | Methods for enhancing recombinant adeno-associated virus yield |
WO2021209521A1 (en) | 2020-04-14 | 2021-10-21 | Genethon | Vectors for the treatment of acid ceramidase deficiency |
WO2021211753A1 (en) | 2020-04-15 | 2021-10-21 | Voyager Therapeutics, Inc. | Tau binding compounds |
WO2021247995A2 (en) | 2020-06-04 | 2021-12-09 | Voyager Therapeutics, Inc. | Compositions and methods of treating neuropathic pain |
WO2021257595A1 (en) | 2020-06-15 | 2021-12-23 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery for muscular dystrophies |
WO2022011099A1 (en) | 2020-07-08 | 2022-01-13 | Regents Of The University Of Minnesota | Modified hexosaminidase and uses thereof |
WO2022018638A1 (en) | 2020-07-21 | 2022-01-27 | Crispr Therapeutics Ag | Genome-editing compositions and methods to modulate faah for treatment of neurological disorders |
WO2022026410A2 (en) | 2020-07-27 | 2022-02-03 | Voyager Therapeutics, Inc | Compositions and methods for the treatment of niemann-pick type c1 disease |
WO2022026409A1 (en) | 2020-07-27 | 2022-02-03 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
WO2022032153A1 (en) | 2020-08-06 | 2022-02-10 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
WO2022047201A1 (en) | 2020-08-27 | 2022-03-03 | University Of Iowa Research Foundation | Gene knock-out for treatment of glaucoma |
WO2022055791A1 (en) | 2020-09-08 | 2022-03-17 | Sarepta Therapeutics, Inc. | Systemic delivery of adeno-associated virus vector expressing g-sarcoglycan and the treatment of muscular dystrophy |
US11925675B2 (en) | 2020-09-08 | 2024-03-12 | Sarepta Therapeutics, Inc. | Systemic delivery of adeno-associated virus vector expressing gamma-sarcoglycan and the treatment of muscular dystrophy |
WO2022060841A2 (en) | 2020-09-15 | 2022-03-24 | Research Institute At Nationwide Children's Hospital | Aav-mediated homology-independent targeted integration gene editing for correction of diverse dmd mutations in patients with muscular dystrophy |
WO2022067257A1 (en) | 2020-09-28 | 2022-03-31 | Research Institute At Nationwide Children's Hospital | Products and methods for treating muscular dystrophy |
WO2022070107A1 (en) | 2020-09-30 | 2022-04-07 | Crispr Therapeutics Ag | Materials and methods for treatment of amyotrophic lateral sclerosis |
WO2022094461A1 (en) | 2020-11-02 | 2022-05-05 | Biomarin Pharmaceutical Inc. | Process for enriching adeno-associated virus |
WO2022115745A1 (en) | 2020-11-30 | 2022-06-02 | Research Institute At Nationwide Children's Hospital | Compositions and methods for treating facioscapulohumeral muscular dystrophy (fshd) |
WO2022133246A1 (en) | 2020-12-17 | 2022-06-23 | Vertex Pharmaceuticals Incorporated | Compositions and methods for editing beta-globin for treatment of hemaglobinopathies |
WO2022164860A1 (en) | 2021-01-27 | 2022-08-04 | Research Institute At Nationwide Children's Hospital | Materials and methods for the treatment of lysosomal acid lipase deficiency (lal-d) |
WO2022169922A1 (en) | 2021-02-03 | 2022-08-11 | Research Institute At Nationwide Children's Hospital | Compositions and methods for treating disease associated with dux4 overexpression |
WO2022170082A1 (en) | 2021-02-05 | 2022-08-11 | Regents Of The University Of Minnesota | Methods for preventing cardiac or skeletal defects in diseases including mucopolysaccharidoses |
WO2022170038A1 (en) | 2021-02-05 | 2022-08-11 | Amicus Therapeutics, Inc. | Adeno-associated virus delivery of cln3 polynucleotide |
WO2022187571A1 (en) | 2021-03-04 | 2022-09-09 | Research Institute At Nationwide Children's Hospital | Products and methods for treatment of dystrophin-based myopathies using crispr-cas9 to correct dmd exon duplications |
WO2022188797A1 (en) | 2021-03-09 | 2022-09-15 | Huigene Therapeutics Co., Ltd. | Engineered crispr/cas13 system and uses thereof |
WO2022221424A1 (en) | 2021-04-13 | 2022-10-20 | Research Institute At Nationwide Children's Hospital | Recombinant adeno-associated virus encoding methyl-cpg binding protein 2 for treating pitt hopkins syndrome via intrathecal delivery |
WO2022221529A1 (en) | 2021-04-16 | 2022-10-20 | Asklepios Biopharmaceutical, Inc. | Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response |
WO2022226334A1 (en) | 2021-04-23 | 2022-10-27 | Research Institute At Nationwide Children's Hospital | Products and methods for treating muscular dystrophy |
WO2022234295A1 (en) | 2021-05-07 | 2022-11-10 | Ucl Business Ltd | Abca4 genome editing |
WO2022245675A1 (en) | 2021-05-17 | 2022-11-24 | Sarepta Therapeutics, Inc. | Production of recombinant aav vectors for treating muscular dystrophy |
EP4108263A2 (en) | 2021-06-02 | 2022-12-28 | Research Institute at Nationwide Children's Hospital | Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a |
WO2022258753A1 (en) | 2021-06-11 | 2022-12-15 | Bayer Aktiengesellschaft | Type v rna programmable endonuclease systems |
EP4101928A1 (en) | 2021-06-11 | 2022-12-14 | Bayer AG | Type v rna programmable endonuclease systems |
WO2023283962A1 (en) | 2021-07-16 | 2023-01-19 | Huigene Therapeutics Co., Ltd. | Modified aav capsid for gene therapy and methods thereof |
WO2023018854A2 (en) | 2021-08-11 | 2023-02-16 | Solid Biosciences Inc. | Treatment of muscular dystrophy |
WO2023034994A1 (en) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
WO2023034989A1 (en) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
WO2023034990A1 (en) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
WO2023034996A1 (en) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
WO2023034997A1 (en) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
WO2023034980A1 (en) | 2021-09-03 | 2023-03-09 | Bomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
WO2023036669A1 (en) | 2021-09-07 | 2023-03-16 | Bayer Aktiengesellschaft | Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof |
EP4144841A1 (en) | 2021-09-07 | 2023-03-08 | Bayer AG | Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof |
WO2023042104A1 (en) | 2021-09-16 | 2023-03-23 | Novartis Ag | Novel transcription factors |
WO2023044483A2 (en) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
WO2023060215A1 (en) | 2021-10-07 | 2023-04-13 | Research Institute At Nationwide Children's Hospital | Products and methods for myelin protein zero silencing and treating cmt1b disease |
WO2023060233A1 (en) | 2021-10-08 | 2023-04-13 | Amicus Therapeutics, Inc. | Biomarkers for lysosomal storage diseases |
EP4219726A1 (en) | 2021-10-15 | 2023-08-02 | Research Institute at Nationwide Children's Hospital | Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy |
WO2023077078A1 (en) | 2021-10-29 | 2023-05-04 | Ultragenyx Pharmaceutical Inc. | Engineered cell lines for increased production of recombinant adeno-associated virus (raav) |
WO2023091949A2 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
EP4186919A1 (en) | 2021-11-30 | 2023-05-31 | Research Institute at Nationwide Children's Hospital | Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy |
EP4198046A1 (en) | 2021-12-16 | 2023-06-21 | Genethon | Alpha-sarcoglycan gene transfer increase using modified itr sequences |
EP4198134A1 (en) | 2021-12-16 | 2023-06-21 | Genethon | Gamma-sarcoglycan gene transfer increase using modified itr sequences |
EP4198048A1 (en) | 2021-12-16 | 2023-06-21 | Genethon | Calpain-3 gene transfer increase using modified itr sequences |
EP4198047A1 (en) | 2021-12-16 | 2023-06-21 | Genethon | Fukutin related protein gene transfer increase using modified itr sequences |
WO2023111102A1 (en) | 2021-12-16 | 2023-06-22 | Genethon | Alpha-sarcoglycan gene transfer increase using modified itr sequences |
WO2023111106A1 (en) | 2021-12-16 | 2023-06-22 | Genethon | Fukutin related protein gene transfer increase using modified itr sequences |
WO2023111107A1 (en) | 2021-12-16 | 2023-06-22 | Genethon | Calpain-3 gene transfer increase using modified itr sequences |
WO2023111104A1 (en) | 2021-12-16 | 2023-06-22 | Genethon | Gamma-sarcoglycan gene transfer increase using modified itr sequences |
WO2023122669A1 (en) | 2021-12-21 | 2023-06-29 | Research Institute At Nationwide Children's Hospital | Materials and methods for the treatment of limb girdle muscular dystrophy |
WO2023118068A1 (en) | 2021-12-23 | 2023-06-29 | Bayer Aktiengesellschaft | Novel small type v rna programmable endonuclease systems |
US12037616B2 (en) | 2022-03-01 | 2024-07-16 | Crispr Therapeutics Ag | Methods and compositions for treating angiopoietin-like 3 (ANGPTL3) related conditions |
WO2023168400A2 (en) | 2022-03-03 | 2023-09-07 | Research Institute At Nationwide Children's Hospital | Materials and methods for the treatment of eif2b5 mutations and diseases resulting therefrom |
WO2023178067A1 (en) * | 2022-03-16 | 2023-09-21 | Rutgers, The State University Of New Jersey | Controlled muscle‐specific gene delivery |
WO2023196818A1 (en) | 2022-04-04 | 2023-10-12 | The Regents Of The University Of California | Genetic complementation compositions and methods |
WO2023214346A1 (en) | 2022-05-06 | 2023-11-09 | Novartis Ag | Novel recombinant aav vp2 fusion polypeptides |
WO2023240177A1 (en) | 2022-06-08 | 2023-12-14 | Research Instiitute At Nationwide Children's Hospital | Products and methods for treating diseases or conditions associated with mutant or pathogenic kcnq3 expression |
WO2023240236A1 (en) | 2022-06-10 | 2023-12-14 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of spinal muscular atrophy related disorders |
WO2023237587A1 (en) | 2022-06-10 | 2023-12-14 | Bayer Aktiengesellschaft | Novel small type v rna programmable endonuclease systems |
WO2024011115A1 (en) | 2022-07-06 | 2024-01-11 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus delivery of cln1 polynucleotide |
WO2024035782A1 (en) | 2022-08-10 | 2024-02-15 | Aav Gene Therapeutics, Inc. | Aav-mediated intramuscular delivery of insulin |
WO2024059739A1 (en) | 2022-09-15 | 2024-03-21 | Voyager Therapeutics, Inc. | Tau binding compounds |
WO2024064913A1 (en) | 2022-09-23 | 2024-03-28 | Sarepta Therapeutics, Inc. | Recombinant aav vectors for treating muscular dystrophy |
WO2024081706A1 (en) | 2022-10-11 | 2024-04-18 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus delivery to treat spinal muscular atrophy with respiratory distress type 1 (smard1) and charcot-marie-tooth type 2s (cmt2s) |
WO2024092171A1 (en) | 2022-10-26 | 2024-05-02 | University Of Iowa Research Foundation | Method to deliver large genes using virus and a dna recombination system |
WO2024092126A1 (en) | 2022-10-27 | 2024-05-02 | Cargo Therapeutics, Inc. | Compositions and methods for improved immunotherapies |
WO2024129743A2 (en) | 2022-12-13 | 2024-06-20 | Bluerock Therapeutics Lp | Engineered type v rna programmable endonucleases and their uses |
WO2024145474A2 (en) | 2022-12-29 | 2024-07-04 | Voyager Therapeutics, Inc. | Compositions and methods for regulating mapt |
WO2024151982A1 (en) | 2023-01-13 | 2024-07-18 | Amicus Therapeutics, Inc. | Gene therapy constructs for the treatment of pompe disease |
WO2024163560A1 (en) | 2023-02-01 | 2024-08-08 | Sarepta Therapeutics, Inc. | Raav production methods |
WO2024163737A1 (en) | 2023-02-02 | 2024-08-08 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta 1 deficiency |
WO2024163012A1 (en) | 2023-02-02 | 2024-08-08 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
WO2024168276A2 (en) | 2023-02-09 | 2024-08-15 | Cargo Therapeutics, Inc. | Compositions and methods for immunotherapies |
Also Published As
Publication number | Publication date |
---|---|
AU4596396A (en) | 1996-06-26 |
EP0796339A1 (en) | 1997-09-24 |
JPH10511264A (en) | 1998-11-04 |
AU707866B2 (en) | 1999-07-22 |
CA2207927A1 (en) | 1996-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU707866B2 (en) | Packaging cell lines for generation of high titers of recombinant AAV vectors | |
US6924128B2 (en) | Packaging cell lines for generation of high titers of recombinant AAV vectors | |
WO1996017947A9 (en) | Packaging cell lines for generation of high titers of recombinant aav vectors | |
US6541258B2 (en) | AAV split-packaging genes and cell lines comprising such genes for use in the production of recombinant AAV vectors | |
AU688428B2 (en) | Generation of high titers of recombinant AAV vectors | |
US6936466B2 (en) | Transcriptionally-activated AAV inverted terminal repeats (ITRs) for use with recombinant AAV vectors | |
US6642051B1 (en) | Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors | |
EP0728214B1 (en) | Stable cell lines capable of expressing the adeno-associated virus replication gene | |
WO1998027204A9 (en) | Aav split-packaging genes and cell lines comprising such genes for use in the production of recombinant aav vectors | |
CA2269661A1 (en) | Recombinase-activatable aav packaging cassettes for use in the production of aav vectors | |
CA2304801C (en) | Transcriptionally-activated aav inverted terminal repeats (itrs) for use with recombinant aav vectors | |
AU758541B2 (en) | Amplifiable adeno-associated virus (AAV) packaging cassettes for the production of recombinant AAV vectors | |
AU2003203790B2 (en) | Transcriptionally-activated AAV inverted terminal repeats (ITRs) for use with recombinant AAV vectors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1995 564167 Date of ref document: 19951218 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
COP | Corrected version of pamphlet |
Free format text: PAGES 1/8-4/8,6/8 AND 7/8,DRAWINGS,REPLACED BY NEW PAGES BEARING THE SAME NUMBER |
|
ENP | Entry into the national phase |
Ref document number: 2207927 Country of ref document: CA Ref country code: CA Ref document number: 2207927 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995944069 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995944069 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995944069 Country of ref document: EP |